0.9711267453	aplastic anemia
0.9698493411	hearing loss
0.9689232874	lipid peroxidation
0.9664865485	breast cancer
0.9656063057	folic acid
0.9655783808	valproic acid
0.9644690502	dilated cardiomyopathy
0.9643823880	diabetes insipidus
0.9636102744	diabetes mellitus
0.9628457411	spinal cord
0.9624687340	ventricular fibrillation
0.9615547948	uric acid
0.9615179290	oral contraceptives
0.9614890655	venous thromboembolism
0.9612018808	hemolytic anemia
0.9611135927	platelet aggregation
0.9585421854	reactive oxygen species
0.9583511627	prostate cancer
0.9579526401	bile duct
0.9570820801	sinus rhythm
0.9569023162	white matter
0.9568968248	ejection fraction
0.9567549577	magnetic resonance imaging
0.9567490390	erectile dysfunction
0.9563242728	cerebrospinal fluid
0.9558210625	artery calcification
0.9557391595	thrombotic microangiopathy
0.9554333857	calcium chloride
0.9553592160	bone marrow
0.9549986696	visual field
0.9546753904	folinic acid
0.9534053898	sodium chloride
0.9530734105	qt interval
0.9529551003	odds ratio
0.9523464772	optic neuropathy
0.9523438443	chest pain
0.9522542832	tricyclic antidepressant
0.9522440981	weight gain
0.9516317162	qt prolongation
0.9516067470	substantia nigra
0.9515150342	endometrial cancer
0.9503755894	nephrotic syndrome
0.9502368330	blood vessels
0.9499292757	rheumatoid arthritis
0.9499279070	creatine kinase
0.9496644313	visual acuity
0.9495078697	acute lymphoblastic leukemia
0.9492435776	ethinyl estradiol
0.9486571190	contrast medium
0.9475760297	atrial fibrillation
0.9475349287	bipolar disorder
0.9474500054	intracerebral hemorrhage
0.9466348347	myocardial ischemia
0.9464547811	statistical significance
0.9463167527	diabetic nephropathy
0.9453517160	temporal lobe epilepsy
0.9449939693	granule cell
0.9436922215	amino acid
0.9432229448	relative risk
0.9429608809	calcium channel blockers
0.9423931343	magnetic resonance
0.9421905300	electron microscopy
0.9417808122	sexual dysfunction
0.9415747470	tranexamic acid
0.9412449232	visual hallucinations
0.9412345833	myocardial infarction
0.9410759157	superoxide dismutase
0.9410738104	vitamin d3
0.9403362791	globus pallidus
0.9399973358	neuroleptic malignant syndrome
0.9397216975	interstitial nephritis
0.9396747039	nephrogenic diabetes insipidus
0.9389605056	cardiac arrest
0.9387030681	emergency department
0.9385155564	ventricular arrhythmias
0.9382865565	oxidative stress
0.9381059539	optic nerve
0.9377522037	puromycin aminonucleoside
0.9375982163	nitric oxide
0.9375945632	status epilepticus
0.9373765017	peripheral neuropathy
0.9363537635	subarachnoid hemorrhage
0.9357053550	angiotensin converting enzyme
0.9356561887	wild type
0.9350142032	hemolytic uremic syndrome
0.9346725675	intensive care unit
0.9339628229	angiotensin ii
0.9338902605	spinal anaesthesia
0.9330526316	crack cocaine
0.9329475950	ventricular tachycardia
0.9320810967	respiratory failure
0.9317421457	postoperative delirium
0.9313569610	creatinine clearance
0.9302460842	randomly allocated
0.9298846861	endothelial cells
0.9297090294	orthostatic hypotension
0.9290718178	local anesthetics
0.9289175426	intraocular pressure
0.9287596490	dentate gyrus
0.9286016068	beta blockers
0.9285857346	hemorrhagic cystitis
0.9284392872	secondary hyperalgesia
0.9283412020	local anesthetic
0.9281785751	liver transplantation
0.9280045294	ovarian cancer
0.9274083891	bladder cancer
0.9263066602	migraine attack
0.9262319267	blood flow
0.9261908378	lung cancer
0.9257760469	passive avoidance
0.9252366521	sodium nitroprusside
0.9240755734	torsade de pointes
0.9236852633	rating scale
0.9227284041	heart failure
0.9210174399	pulmonary hypertension
0.9207276756	logistic regression
0.9200542626	congestive heart failure
0.9184550672	adverse event
0.9177146056	myocardial injury
0.9173215345	liver biopsy
0.9166481884	cognitive impairment
0.9162333359	nmda receptor
0.9149371773	bone marrow transplantation
0.9146605494	cholestatic hepatitis
0.9137831955	alzheimer's disease
0.9136764891	cognitive deficits
0.9136659736	renal failure
0.9128405006	systolic blood pressure
0.9124310802	metastatic breast cancer
0.9121003965	animal model
0.9117107028	cell proliferation
0.9114045290	parkinson's disease
0.9113408878	mm hg
0.9103670872	coronary artery
0.9101798716	acute liver failure
0.9095102142	heart rate
0.9084144317	cardiac output
0.9082175837	receptor agonists
0.9066365163	transplant recipients
0.9065661681	locomotor activity
0.9062527181	glomerular filtration rate
0.9056313393	mortality rate
0.9047423683	ergotamine caffeine
0.9044845628	fulminant hepatic failure
0.9044718568	extrapyramidal symptoms
0.9042905052	gamma aminobutyric acid
0.9038555075	liver transplant
0.9036724088	body surface area
0.9028234416	gene expression
0.9013104219	physical examination
0.9012293525	medical records
0.9009347279	oxygen consumption
0.9007149557	renal insufficiency
0.8998709983	torsades de pointes
0.8998415114	smooth muscle
0.8995056334	glyceryl trinitrate
0.8987263702	adverse reactions
0.8976916987	vascular resistance
0.8974818694	body weight
0.8966371220	ecstasy users
0.8960018480	muscle rigidity
0.8959597448	cerebral edema
0.8958864025	hepatic injury
0.8945650572	hepatitis b virus
0.8943747469	postmenopausal women
0.8942984876	serotonin reuptake
0.8940215689	stem cell
0.8934789351	dobutamine stress
0.8934369524	mental status
0.8930823469	complete remission
0.8928562106	ocular hypertension
0.8916950028	passive avoidance task
0.8905049263	vitamin e
0.8904241354	creatinine concentration
0.8903295303	acute renal failure
0.8899298459	amphotericin b
0.8888190336	mg per deciliter
0.8885717144	tubular damage
0.8884138558	granule cells
0.8880098539	liver failure
0.8875989911	life threatening
0.8866740390	st segment
0.8866647395	left ventricular
0.8865182794	channel blocker
0.8864405960	basement membrane
0.8860152561	heart block
0.8856743190	liver function tests
0.8854876537	appetite suppressants
0.8849755710	cross sectional
0.8846524473	memory impairment
0.8843591858	blood pressure
0.8840797184	channel blockers
0.8837810234	liposomal doxorubicin
0.8834177148	mg bid
0.8817697020	acetaminophen induced alf
0.8805189990	calcineurin inhibitor
0.8802522360	ng ml
0.8800377774	case summary
0.8798616183	protein expression
0.8798511524	calcium channel
0.8793643358	acute hepatitis
0.8777560094	protective role
0.8775183961	cpa ee
0.8774590383	mg dl
0.8760428774	platelet count
0.8755323085	open label
0.8749856768	tubular necrosis
0.8739271259	cognitive functions
0.8739201453	mg m2
0.8736519398	phenytoin sodium
0.8731686946	antitumor activity
0.8723866993	milk alkali syndrome
0.8721350650	cb 3717
0.8715078181	heparin induced thrombocytopenia
0.8702192261	pre existing
0.8693075915	cognitive function
0.8686032648	sodium channel
0.8650538615	coronary artery disease
0.8647787062	micrograms kg
0.8641658858	adverse drug reaction
0.8639650180	healthy volunteers
0.8632011252	receptor antagonist
0.8617562833	6 ohda
0.8613894985	end diastolic
0.8612406233	blood brain barrier
0.8604039424	molecular weight
0.8602684188	remained unchanged
0.8599059788	dopamine d2
0.8598432856	beta blocker
0.8596244176	action potential
0.8585019346	nmda receptors
0.8572850197	urinary bladder
0.8566010446	dependent manner
0.8548277560	serum creatinine
0.8543706892	sustained release
0.8541857990	case series
0.8541350650	fk 506
0.8533937606	drug interactions
0.8533017416	mrna levels
0.8530515351	receptor agonist
0.8513290011	adverse events
0.8505735515	levodopa induced dyskinesias
0.8495874179	converting enzyme
0.8494135960	cardiac arrhythmias
0.8493950992	short term
0.8486387447	systemic vascular resistance
0.8475309011	acute interstitial nephritis
0.8464420705	risk factors
0.8464311708	phase ii
0.8463471892	end stage renal disease
0.8456451615	mpo anca
0.8450715589	5 fu
0.8450322403	sprague dawley
0.8448413898	acute myocardial infarction
0.8433257908	hepatitis b
0.8425044142	mitomycin c
0.8424055177	disease progression
0.8416501657	renal injury
0.8412593051	left ventricular dysfunction
0.8404665954	microg kg
0.8404638149	haloperidol induced catalepsy
0.8397479101	weight loss
0.8390977502	double blind
0.8384705723	ck mb
0.8384257144	statistically significant
0.8384189376	chronic renal failure
0.8369740656	partial response
0.8357737658	nonsteroidal anti inflammatory
0.8345060396	renal function
0.8327216691	abdominal pain
0.8327162035	intravenous ribavirin
0.8324462788	l dopa
0.8316717989	scopolamine induced amnesia
0.8300375783	long lasting
0.8300096322	cell death
0.8294019271	receptor antagonists
0.8289164970	liver injury
0.8286536645	cardiovascular disease
0.8286058249	clinical trials
0.8284336444	hepatic failure
0.8275900989	immunodeficiency virus
0.8255651556	cardiac dysfunction
0.8252831532	vitamin d
0.8243183011	spontaneously hypertensive rats
0.8240258436	glomerular filtration
0.8216961021	balb c mice
0.8158177799	beta adrenergic
0.8156914574	microg 0.5 microl
0.8140187678	serum creatinine levels
0.8139413554	beta adrenoceptor
0.8135297829	l arginine
0.8121929299	pilot study
0.8121569796	angiotensin converting enzyme inhibitor
0.8095033847	beneficial effect
0.8091166171	male sprague dawley rats
0.8045587063	long term
0.8020391909	wistar rats
0.8013474811	adult male
0.7998676933	randomly assigned
0.7974039272	gamma aminobutyric
0.7972758061	renal damage
0.7949902656	male wistar rats
0.7921394958	observation period
0.7908945719	renal dysfunction
0.7901987650	anti inflammatory
0.7901706877	severe adenovirus
0.7889856258	urinary protein
0.7886617994	elevated plus maze
0.7836504798	cck 8
0.7826491048	vitamin c
0.7817580575	controlled trial
0.7815399520	acc 9653
0.7812747101	report describes
0.7791912480	arterial pressure
0.7790880851	wt mice
0.7788285468	case reports
0.7754953011	doxorubicin induced cardiotoxicity
0.7751864373	renin angiotensin
0.7748017101	beneficial effects
0.7731083824	healthy subjects
0.7719392366	single agent
0.7707616677	drug interaction
0.7700857768	body surface
0.7689583000	converting enzyme inhibitor
0.7672525936	protective effects
0.7663714692	mk 801
0.7659376418	animal models
0.7656902365	abstract truncated at 250 words
0.7647696882	clinically significant
0.7640216646	aminobutyric acid
0.7595265094	l noarg
0.7590467179	risperidone
0.7578143194	temporal lobe
0.7565132057	myopathy
0.7554747170	rat heart
0.7546995288	placebo controlled
0.7546641180	head and neck
0.7546443874	d2 receptor
0.7499783325	5 fluorouracil
0.7487225970	adverse effects
0.7465773917	mg kg s.c
0.7459792489	angioedema
0.7453287997	combination therapy
0.7448980538	dose dependently
0.7447506266	chronic hepatitis c
0.7446680340	brain damage
0.7438321721	hyperprolactinemia
0.7424338808	prolactin
0.7406911387	nicotine
0.7398954954	ml min
0.7398198693	cumulative dose
0.7393396618	case control study
0.7386661339	caffeine
0.7376931644	adenovirus disease
0.7375291143	normal saline
0.7374496625	jaundice
0.7366153093	arterial blood pressure
0.7364148847	smoking
0.7363508783	citrate
0.7355258082	fetal
0.7354476878	d penicillamine
0.7354109461	neuromuscular
0.7352476736	5 ht
0.7325822388	delirium
0.7325245150	liver disease
0.7322901351	mania
0.7315649342	headache
0.7310257622	magnesium
0.7309925727	hypersensitivity
0.7308786096	sprague dawley rats
0.7308053220	pg 9
0.7297526534	carotid
0.7293747003	significantly attenuated
0.7292341387	ribavirin
0.7288848469	hemolysis
0.7288006557	pulse
0.7287512052	sleep
0.7286357511	epidural
0.7282491474	dipyridamole
0.7277791856	phase ii study
0.7271131932	higher doses
0.7265533340	serum calcium
0.7264758198	micromol l
0.7260600388	renin angiotensin system
0.7257247101	fluoxetine
0.7253711596	ecstasy
0.7253415717	heavy
0.7249053018	isoproterenol induced myocardial infarction
0.7247537036	antiepileptic drug
0.7240852153	mitochondrial
0.7237432539	data suggest
0.7235574483	cocaine users
0.7232729563	heart disease
0.7222296248	barium
0.7214705492	syncope
0.7213481680	neonatal
0.7210351838	hypoxia
0.7201260360	cerebellar
0.7195294351	dose limiting
0.7193704920	hydrocortisone
0.7193600941	neurologic
0.7192631119	nitroprusside
0.7192611626	diuretic
0.7190601701	phenytoin
0.7189473605	case report
0.7187826052	antiarrhythmic
0.7187198797	atpase
0.7180670761	consecutive days
0.7176264962	manic
0.7173985596	auditory
0.7169901926	eye
0.7168559821	organic
0.7163240515	maleate
0.7155758132	mg kg
0.7152986234	adrenaline
0.7152189930	estrogen
0.7148607152	peripheral blood
0.7134384412	significant increases
0.7134337338	cocaine associated chest pain
0.7133596591	acetaminophen
0.7123002227	methamphetamine
0.7119752787	aortic
0.7119035256	risk factor
0.7114723778	repair
0.7114490081	brainstem
0.7111227348	learning and memory
0.7109889037	avoidance task
0.7108303143	warfarin
0.7106658849	angiography
0.7104668776	ocular
0.7103804790	estradiol
0.7096507360	apnea
0.7094585583	center
0.7090667641	consolidation
0.7090448124	clinical practice
0.7089623064	kg min
0.7087456865	tolerance
0.7081366431	dobutamine
0.7073325881	ct
0.7072136081	high dose
0.7066153887	dox
0.7059511392	misoprostol
0.7057767050	pupillary
0.7053707888	g dl
0.7052792981	antibodies
0.7050200477	meth
0.7049038135	caspase 3
0.7043852750	intramuscular
0.7040811496	simvastatin
0.7038166992	neural
0.7031659144	basic
0.7031375547	proximal
0.7031257752	intervention
0.7024396654	lovastatin
0.7024396654	quinine
0.7020747830	subacute
0.7017681199	stroke
0.7016531911	allograft
0.7016405049	dual
0.7013151225	psychiatric
0.7011166473	vasopressin
0.7009131001	platelet
0.7008847641	lidocaine
0.7008567790	reperfusion
0.7008209621	methadone
0.7006407720	fear
0.7006129768	reserpine
0.6999530551	lv
0.6998852051	calcitonin
0.6998130804	iron
0.6997237297	single injection
0.6996479781	map
0.6995837570	bradykinin
0.6991365223	skin
0.6991021275	adriamycin
0.6990092679	protective effect
0.6988151654	timolol
0.6986830904	optimal
0.6986441909	adenosine
0.6983880545	captopril
0.6982037793	aids
0.6980184335	third generation
0.6978984575	desipramine
0.6977577080	scopolamine
0.6976559556	genetic
0.6976495319	lindane
0.6975409935	bupropion
0.6973821825	fever
0.6973103614	amiodarone
0.6971717711	metformin
0.6971523252	olanzapine
0.6964166367	dexamethasone
0.6963721671	sotalol
0.6960950694	hdl
0.6951261121	cutaneous
0.6949236884	thrombotic
0.6946467348	diagnostic
0.6945698751	index
0.6941982786	pituitary
0.6939874026	tamoxifen
0.6939565928	superoxide
0.6939289301	losartan
0.6937347829	leg
0.6937022677	cranial
0.6936993643	akathisia
0.6936364567	survival
0.6935951878	global
0.6934482451	previously reported
0.6930776310	endothelial
0.6929850835	pharmacology
0.6926934665	95 percent confidence interval
0.6925487562	midazolam
0.6922667860	dexmedetomidine
0.6921100063	epileptic
0.6919820905	cell lung
0.6915229813	deep
0.6914339685	dose dependent
0.6912849508	folate
0.6912614199	antidepressants
0.6911970475	morphological
0.6911688808	theophylline
0.6911112952	etoposide
0.6907022114	renal transplant
0.6905526449	na
0.6901806250	capsaicin
0.6901591853	focal
0.6899764701	methyldopa
0.6896174218	ketoconazole
0.6893990868	alf
0.6893851701	older
0.6892449674	medial
0.6887104050	control subjects
0.6886965061	ciprofloxacin
0.6884775493	mri
0.6883979931	cholesterol
0.6881815855	sham
0.6880982016	mmol l
0.6880066925	immunosuppressive
0.6879445214	tobramycin
0.6878490257	piperacillin
0.6878209805	md
0.6877794988	hallucinations
0.6876200922	argatroban
0.6875832326	melatonin
0.6875238783	azathioprine
0.6874601913	gastrointestinal
0.6872837884	cholestasis
0.6871124933	mannitol
0.6869956297	treated rats
0.6868590254	thalidomide
0.6868054564	electrical
0.6864434676	cisapride
0.6863405432	ethambutol
0.6861877361	cortical
0.6859944225	dyskinetic
0.6856581140	lifetime
0.6854196994	p450
0.6853787267	hiv
0.6853729783	apomorphine
0.6852044203	fentanyl
0.6849566689	digoxin
0.6849337775	hyperalgesia
0.6845873412	anesthesia
0.6844533729	hz
0.6841101166	enalapril
0.6836676678	biological
0.6833568859	vincristine
0.6832050668	vigabatrin
0.6831809846	pd
0.6831760047	migraine
0.6831454638	anaesthesia
0.6830012625	glucose
0.6829257497	clinical trial
0.6828940324	gamma
0.6828748771	methylphenidate
0.6828212388	glial
0.6826094475	opioid
0.6825983695	grade
0.6824274770	spectrum
0.6824274770	excessive
0.6824141216	suxamethonium
0.6823450315	force
0.6822994804	bupivacaine
0.6822562611	succinylcholine
0.6821105774	glucocorticoid
0.6821028331	spironolactone
0.6820300406	flumazenil
0.6819212123	histamine
0.6816031547	prolactin levels
0.6815349073	ace
0.6812551019	anesthetized rats
0.6808319655	lamivudine
0.6808220542	rg1
0.6806615553	diazinon
0.6805761185	paroxetine
0.6805631031	vas
0.6804612549	anxiety
0.6802265603	recurrence
0.6801519716	snr
0.6801199863	coagulation
0.6798620300	testosterone
0.6797624810	fluconazole
0.6797624810	aconitine
0.6787544628	motility
0.6786397890	bleeding
0.6785621322	dialysis
0.6784960744	depressed
0.6784544779	cns
0.6784487384	busulfan
0.6783109899	pneumonia
0.6783103088	basal
0.6782677096	surgical
0.6781810850	haloperidol
0.6781324616	ht
0.6779452718	glomeruli
0.6777590436	oxytocin
0.6776963439	quetiapine
0.6775924313	transgenic
0.6775308858	ammonia
0.6774860783	medicine
0.6773852294	intracranial
0.6773588460	carboplatin
0.6771177772	percutaneous
0.6771001506	autism
0.6770790327	non steroidal anti inflammatory
0.6770509253	metoprolol
0.6770297414	neuropathic
0.6770166763	thyroid
0.6765874224	myoclonus
0.6765289048	potentiation
0.6764285474	balb c
0.6763428727	corticosteroids
0.6763269241	transfusion
0.6763123932	metronidazole
0.6763123932	diffusion
0.6762710285	task
0.6762148201	children's
0.6759087979	conversion
0.6757136258	hyperkalemia
0.6756366933	illness
0.6754385853	adr
0.6754219791	trazodone
0.6754219791	ranitidine
0.6753872341	sensitization
0.6751285819	ototoxicity
0.6750992545	nitroglycerin
0.6750647899	past
0.6750172220	a1
0.6748704604	induced convulsions
0.6747703192	bromocriptine
0.6747220660	remifentanil
0.6746270119	tremor
0.6745477556	metabolic
0.6739518013	nuclear
0.6739067688	aspirin
0.6738957525	massive
0.6738760276	naloxone
0.6737909897	cis
0.6737614703	penicillin
0.6736155017	bcnu
0.6734006651	glaucoma
0.6733602635	pcr
0.6732850935	tumors
0.6732771756	angiogenesis
0.6731096079	esrd
0.6730344646	segmental
0.6729842222	sirolimus
0.6728704827	disulfiram
0.6726992111	indomethacin
0.6725173035	hydrogen
0.6722112112	multicenter
0.6720596771	bortezomib
0.6719093358	isoproterenol
0.6718901691	pg
0.6717348186	norepinephrine
0.6714782030	university
0.6714686666	rhabdomyolysis
0.6714047955	crocin
0.6713817453	physical
0.6712739003	anaemia
0.6708815649	toxicities
0.6708392187	neutropenia
0.6708252600	structure
0.6708016619	wt
0.6707579975	permeability
0.6706765025	propylthiouracil
0.6706749391	dna
0.6705611561	ich
0.6705117710	il
0.6704004659	field
0.6702821478	hippocampal
0.6702255694	lithium
0.6701269637	neuropsychiatric
0.6697278428	interferon
0.6695840791	mitral
0.6695807225	intrarenal
0.6695444377	significantly lower
0.6694461150	intra
0.6694386959	latency
0.6692291659	ppa
0.6690363748	resting
0.6688551436	hbv
0.6686949022	hematologic
0.6686319626	diabetic
0.6685535422	angina
0.6684676845	hit
0.6684516614	isoniazid
0.6683595982	systolic and diastolic
0.6683448759	per cent
0.6683300452	antipsychotic
0.6683230379	azt
0.6680777251	prenatal
0.6680671519	dex
0.6680426184	adenovirus
0.6679944501	myocarditis
0.6679838833	prl
0.6679838833	stz
0.6678760004	state
0.6678681966	ketamine
0.6677947964	stones
0.6677834485	anca
0.6676121738	cin
0.6674394331	food
0.6674219086	ce
0.6671708308	sexual
0.6669368989	valproate
0.6669109238	fk506
0.6666622701	typical
0.6666138034	amb
0.6665708907	kidneys
0.6665599982	variant
0.6662246047	diltiazem
0.6661299229	phenobarbital
0.6659280464	ee
0.6658526128	gem
0.6658029548	vancomycin
0.6657134775	venlafaxine
0.6653165817	persistent
0.6651577494	activated
0.6651151538	repeat
0.6650429875	low doses
0.6650142509	salbutamol
0.6650142509	carbimazole
0.6649849697	vpa
0.6649452354	resuscitation
0.6648294598	pb
0.6646743829	diclofenac
0.6644169646	hiccups
0.6643993833	ibuprofen
0.6643485956	sensitivity
0.6643074066	da
0.6642666296	nifedipine
0.6642415673	enhancement
0.6641928606	tdp
0.6641774079	vte
0.6641590570	organization
0.6641040911	encephalopathy
0.6640361843	ngf
0.6639612689	penicillamine
0.6639017546	differential
0.6638517740	eyes
0.6637859093	trials
0.6636716167	structural
0.6636482934	relation
0.6636481850	levodopa
0.6635152659	bp
0.6634128966	nimodipine
0.6633874839	synthesis
0.6632883861	extracellular
0.6632819228	direct
0.6632641804	mesna
0.6632592920	determination
0.6632047389	enac
0.6631578641	mdma
0.6631535371	hepatocyte
0.6631535371	progesterone
0.6630982476	significantly greater
0.6630829961	maze
0.6630813733	fs
0.6630813733	atra
0.6630813733	drg
0.6630619260	valsartan
0.6630619260	cibenzoline
0.6630500721	strokes
0.6629682224	d1
0.6628964401	ra
0.6627154226	octreotide
0.6626897300	levetiracetam
0.6626161949	qtc
0.6625277770	induced hyperactivity
0.6625111391	srl
0.6624108285	nausea and vomiting
0.6622580727	tonic
0.6622313861	suprofen
0.6621093878	tiapride
0.6620848949	heroin
0.6620551160	fenoldopam
0.6620086585	mental
0.6619755494	ldl
0.6619379222	cardiomyocyte
0.6619096271	iii
0.6618002461	cbz
0.6617814575	nephrotoxicity
0.6617766781	epinephrine
0.6617327485	gtn
0.6616794128	amnesia
0.6616699477	clonidine
0.6616502396	spasm
0.6615960882	mi
0.6615850880	toxic effects
0.6615591759	shr
0.6615591759	cp
0.6614729900	li
0.6614710146	cc
0.6613580397	gm
0.6612676041	snp
0.6612611156	streptozotocin
0.6611944475	conscious rats
0.6610185470	rna
0.6609910461	lesions
0.6609206316	amisulpride
0.6608827328	aggregation
0.6608182894	oc
0.6608012875	improvements
0.6607505106	vip
0.6607497768	atp
0.6607371064	pge2
0.6605991800	ns
0.6605696666	pan
0.6605173768	cardiac toxicity
0.6602788604	vegf
0.6602760574	prostaglandin
0.6602721890	atypical
0.6602521348	bradycardia
0.6602358167	antinociceptive
0.6602358167	prazosin
0.6601287460	alcohol
0.6600644313	potassium
0.6600421496	cox
0.6599409741	white
0.6597201833	kindled
0.6595168530	population
0.6594810034	phenylephrine
0.6594354978	antitumor
0.6594120061	systematic
0.6592933880	synaptic
0.6592933880	cerebellum
0.6592539100	neurotoxicity
0.6592314580	preoperative
0.6591851277	developmental
0.6591629295	troponin
0.6591529258	urinary
0.6591260798	cpa
0.6591245537	hepatocellular
0.6590478518	central nervous system
0.6588381460	myalgia
0.6587295579	mg kg i.v
0.6586658296	catalepsy
0.6584361841	avp
0.6582683141	nsaids
0.6581704501	prilocaine
0.6581317856	mtx
0.6580941997	dorsal
0.6575741017	cm
0.6575047863	ptu
0.6575047863	nag
0.6572811457	sulfasalazine
0.6572811457	replication
0.6572053892	flecainide
0.6570706111	mesangial
0.6570706111	kanamycin
0.6570706111	delta
0.6570706111	prednisolone
0.6570706111	nephrolithiasis
0.6570706111	antimicrobial
0.6569533372	hr
0.6568649228	venous
0.6567104337	head
0.6566113200	csa
0.6564391881	multiple
0.6564184930	halothane
0.6563675608	cystitis
0.6563104055	depression
0.6562961548	gemcitabine
0.6562836842	neuroleptic
0.6560940076	nicotinic
0.6560027387	crossover
0.6559200251	ticlopidine
0.6558665923	3h
0.6558053509	mr
0.6557715347	fasciculations
0.6557341206	recall
0.6553809387	hyperbaric
0.6553809387	stimulus
0.6553809387	labetalol
0.6553728791	idiopathic
0.6552904455	logistic
0.6551124474	procedural
0.6550811575	dermatitis
0.6550390073	pilocarpine
0.6549541893	nmda
0.6549462097	e2
0.6549410817	lt
0.6548316331	recurrent
0.6548005309	echocardiographic
0.6547820125	sulindac
0.6547820125	yohimbine
0.6547820125	indinavir
0.6546930068	lid
0.6545851575	sd
0.6544092877	symptom
0.6543474732	st
0.6543295393	raloxifene
0.6542670227	continuous infusion
0.6541779539	overdose
0.6541640872	offspring
0.6541323484	furosemide
0.6541044615	cd4
0.6539241931	red
0.6538683881	m1
0.6538091953	levobupivacaine
0.6538032940	lateral
0.6537863410	vt
0.6537863410	gi
0.6537590035	mb
0.6537179010	inappropriate
0.6534252106	anp
0.6534252106	ccnu
0.6532631960	pilocarpine induced seizures
0.6532331139	atherosclerosis
0.6532331139	metoclopramide
0.6531785276	pregnant
0.6530119151	electron
0.6529913177	od
0.6529816904	tolerability
0.6529265535	associations
0.6529237636	remission
0.6527849184	sbp
0.6527449393	antidepressant
0.6524315122	postoperatively
0.6523739442	fas
0.6523638547	enflurane
0.6523530155	memory
0.6523429431	hypothyroidism
0.6522286057	cyp
0.6521995921	hippocampus
0.6520082683	pethidine
0.6518731983	ache
0.6518434754	paclitaxel
0.6516154090	extrapyramidal side effects
0.6515590255	flow
0.6515235606	cya
0.6514892065	maternal
0.6514887800	nrf2
0.6514249060	sah
0.6514205041	ca
0.6514156026	cyp3a4
0.6513639766	induced myocardial infarction in rats
0.6512794813	unusual
0.6512747240	contraction
0.6511314489	continuous
0.6510461866	rr
0.6510435925	gr
0.6509610267	immunohistochemistry
0.6509344282	upper
0.6509068171	iso
0.6508750797	mg kg i.p
0.6506815795	cimetidine
0.6506690397	assay
0.6506576157	bbb
0.6506576157	gfr
0.6506567977	sclerosis
0.6506567977	asystole
0.6506081050	phenobarbitone
0.6506069016	d2
0.6506005219	compliance
0.6506005219	verbal
0.6505845446	analyses
0.6505696876	high frequency
0.6505644289	morbidity and mortality
0.6505121858	subarachnoid
0.6504733668	cyclooxygenase
0.6504005456	bone
0.6503662988	cgrp
0.6502311038	second generation
0.6502298274	lh
0.6501843316	tg
0.6501525349	hypokalemia
0.6501405151	bn
0.6501405151	nf
0.6500153511	doxorubicin
0.6499486465	antiviral
0.6499398447	ritonavir
0.6499398447	papaverine
0.6499231526	immune
0.6497987438	intraoperative
0.6497987438	morning
0.6497944286	leukoencephalopathy
0.6497827807	af
0.6495419706	er
0.6495291053	quality
0.6495125929	measure
0.6494675319	systemic
0.6494657649	hospital
0.6494204965	behavioral
0.6493348005	chemical
0.6492893919	catecholamine
0.6489881361	half
0.6489425370	recognition
0.6489396192	curcumin
0.6488997236	extensive
0.6488582543	b2
0.6487980486	cardiotoxicity
0.6487542041	screening
0.6487359856	epo
0.6487359856	dfp
0.6485533897	endometrial
0.6485238585	female rats
0.6483890420	tmp
0.6483872301	poisoning
0.6483872301	osteoporosis
0.6482866983	myoclonic
0.6482864434	parkinsonism
0.6482226749	general
0.6482048845	implications
0.6481823191	abdominal
0.6481711161	ifosfamide
0.6477965842	bepridil
0.6477169244	perfusion
0.6476347537	nms
0.6475998288	asa
0.6474461882	bs
0.6472364033	allergic
0.6471670724	bis
0.6471666149	cholinergic
0.6471167886	quality of life
0.6469761441	unit
0.6468733908	ve
0.6468632362	de novo
0.6467416108	immunohistochemical
0.6465442165	auc
0.6464904199	median
0.6464461325	ps
0.6462353324	rs
0.6462142556	nos
0.6462142556	iop
0.6461237124	levofloxacin
0.6459838165	f344
0.6459581843	rifampicin
0.6455226523	antagonism
0.6454536863	lithium treated
0.6453063105	research
0.6452365725	aki
0.6452365725	apl
0.6452365725	sod
0.6452365725	siadh
0.6450380491	ng
0.6450161659	hbeag
0.6449148614	multivariate
0.6448888284	serotonergic
0.6448854555	apoptosis
0.6448781229	glutamate
0.6447931511	ed
0.6447928344	des
0.6447773988	impairments
0.6447397780	nimesulide
0.6447397780	antithrombotic
0.6447397780	podocyte
0.6447323175	medulla
0.6447282264	complete
0.6446159460	microl
0.6444204941	health
0.6444156207	chf
0.6444036574	temporary
0.6443928689	western
0.6443432538	glomerulosclerosis
0.6442611832	tac
0.6442279823	gentamicin
0.6441856789	cardiac surgery
0.6441239155	mp
0.6440408199	hbsag
0.6439034376	intraocular
0.6438687578	dynamic
0.6437069905	pharmacokinetic
0.6436408561	standard
0.6436141103	manifestations
0.6435671771	pergolide
0.6435338060	antiparkinsonian
0.6435338060	nociceptive
0.6435338060	anxiogenic
0.6434908834	ros
0.6433959649	diseases
0.6433483338	mda
0.6433483338	gsh
0.6433407263	gum
0.6430587700	gastric
0.6430319378	capillary
0.6428779975	current
0.6427688564	gaba
0.6427189943	green
0.6427040854	premature
0.6426694999	retrospective
0.6426380652	hyperthermia
0.6426366944	thromboembolism
0.6424964360	eps
0.6424630467	pupil
0.6423434579	child
0.6421743104	vasculitis
0.6421547140	management
0.6421184389	iv
0.6419533188	chronically
0.6419182934	insulin
0.6419133806	national
0.6419099141	confusion
0.6417979655	ntg
0.6416581234	improvement
0.6415813532	additional
0.6415789297	parenteral
0.6415763681	abstract truncated at
0.6414702086	ptz
0.6414525614	clinically
0.6413827476	vascular
0.6413068740	clarithromycin
0.6412530974	choline
0.6412481082	phase
0.6410586501	heparin
0.6409930461	thrombosis
0.6409073921	aor =
0.6409071577	hepatic
0.6409003283	atropine
0.6408828983	electrophysiological
0.6408756250	microglial
0.6408756250	alprazolam
0.6408756250	climbing
0.6408194273	working
0.6408067186	caa
0.6407142965	images
0.6407142965	hepatocytes
0.6407096332	alfentanil
0.6406724635	verapamil
0.6406399738	dextran
0.6405855198	vasoconstriction
0.6405855198	switching
0.6405410023	odds
0.6405237563	thiopentone
0.6404911975	hctz
0.6404713009	steroids
0.6404470873	eosinophilic
0.6403939048	decreases
0.6403901361	cognitive
0.6402823789	previous
0.6402774831	ester
0.6402774831	extension
0.6402774831	agitation
0.6401953323	significance
0.6401652589	moderate
0.6401082546	bche
0.6400642761	protocols
0.6399258949	dysfunctions
0.6399011096	defects
0.6398729575	icv
0.6398528654	ck
0.6398366301	fewer
0.6396701111	caspase
0.6396444760	di
0.6396360759	stenosis
0.6395529905	ms
0.6394594769	median age
0.6394559541	animal
0.6393835709	haart
0.6393619358	rubella
0.6393285961	malondialdehyde
0.6392434203	av
0.6392240173	reverse
0.6390939851	tri
0.6390144603	conscious
0.6389456359	performance
0.6388672834	hepatitis c
0.6386527994	nsclc
0.6386450714	sulfate
0.6386390578	glutamatergic
0.6386390578	instillation
0.6386390578	leukopenia
0.6385942399	pediatric
0.6385480559	dyskinesia
0.6384927143	high doses
0.6384492744	observations
0.6384156825	crf
0.6384156825	pci
0.6384156825	cn
0.6384151323	net
0.6384046155	hcl
0.6383967449	incontinence
0.6383427789	ach
0.6383404361	serum potassium
0.6382340522	intraperitoneal
0.6381925309	overload
0.6381899690	igf
0.6381065060	negative
0.6380909414	salvage
0.6380909414	chloroquine
0.6380909414	forearm
0.6380909414	mutations
0.6380909414	fibrin
0.6380909414	amikacin
0.6380909414	statins
0.6379075925	protection
0.6378072171	spontaneous
0.6376938727	qt
0.6375608558	sm
0.6374853600	sem
0.6373935400	parp
0.6373302612	dph
0.6373302612	pdtc
0.6373302612	ami
0.6373127205	children
0.6373125524	noradrenergic
0.6372374298	cr
0.6371080211	crossover study
0.6368815119	extended
0.6368815119	cats
0.6368676661	posterior
0.6368581030	ma
0.6368581030	oct
0.6367325273	processes
0.6366680537	core
0.6365389452	dsm
0.6363316621	latencies
0.6361938469	eeg
0.6361049541	c57bl
0.6360610087	panic
0.6360369340	behaviors
0.6360020270	pr
0.6359396713	regional
0.6359283176	attacks
0.6358765330	methotrexate
0.6358758617	hemorrhage
0.6357372316	antigen
0.6356543498	ir
0.6355938321	cholinesterase
0.6355141744	transient
0.6352543125	symptomatic
0.6352532812	channels
0.6351511312	anti
0.6351008610	baseline
0.6350570728	cycle
0.6349621036	abnormal
0.6349438106	cumulative
0.6348145840	dse
0.6348145840	aap
0.6348145840	cy
0.6347368727	short
0.6347174224	stages
0.6347174224	anticholinergic
0.6347059962	protease
0.6346920666	spontaneously hypertensive
0.6346183710	learning
0.6345133038	defect
0.6344771867	prophylactic
0.6343536170	paralysis
0.6342204575	nsaid
0.6340654416	associative
0.6340654416	mutation
0.6340336582	accumbens
0.6340198779	transport
0.6340198779	phosphate
0.6339839182	male rats
0.6339324354	attention
0.6338227542	local
0.6337294142	hemodynamics
0.6337294142	ultrastructural
0.6337294142	thromboembolic
0.6336783429	mechanical
0.6336484444	mitochondria
0.6336475872	carbamazepine
0.6336332967	sc
0.6335711042	signaling
0.6335082089	hypertensive
0.6334358193	amlodipine
0.6334358193	etomidate
0.6333295535	histological
0.6332955631	criteria
0.6332603332	scale
0.6331090992	cardioprotective
0.6329536422	emotional
0.6327182165	bw
0.6326847225	inflammation
0.6326618629	monkeys
0.6325182072	observation
0.6324912984	ip
0.6324826844	selective
0.6324822571	daily
0.6324794186	fetuses
0.6324794186	intradermal
0.6323470549	blood urea
0.6323415919	hypertrophy
0.6322919882	density
0.6322892938	histology
0.6322892938	affective
0.6321249843	tgf
0.6320237444	androgen
0.6319528520	drowsiness
0.6319528520	repetitive
0.6319516073	participants
0.6318566843	mrna
0.6318487236	carbachol
0.6316830323	terbutaline
0.6316825034	primary
0.6314061620	deficit
0.6311815614	gain
0.6311603686	spinal
0.6311361616	lids
0.6311361616	cocs
0.6310951508	liposomal
0.6309421762	database
0.6309029748	pentobarbital
0.6308528903	aneurysms
0.6308162617	topical
0.6306406298	products
0.6306348937	limiting
0.6305232864	al
0.6305105119	worsening
0.6305105119	normalized
0.6304219973	absolute
0.6304219973	prednisone
0.6304219973	ophthalmic
0.6304219973	myelosuppression
0.6304018588	icu
0.6304018588	spect
0.6303201237	albumin
0.6302290110	myeloma
0.6301985559	antineoplastic
0.6301964822	prospective
0.6301661292	pilo
0.6300169645	amphetamine
0.6299683394	tail
0.6299521032	histopathological
0.6298516377	hydroxy
0.6296254403	amiloride
0.6295384678	cck
0.6294098215	practice
0.6293504463	ecg
0.6292659324	pretreatment
0.6292016243	intermittent
0.6291475184	sedation
0.6290569478	leukemia
0.6288086053	controlled
0.6288000395	testing
0.6287645346	isolated
0.6287021850	biopsy
0.6286362589	special
0.6284860994	95 confidence interval
0.6283741474	life
0.6283524505	introduction
0.6282986071	sympathetic
0.6280462279	ages
0.6280367969	serum concentrations
0.6279505530	hemodynamic
0.6278901885	m2
0.6277543312	contralateral
0.6277318472	ultrasound
0.6276870743	position
0.6276870743	absent
0.6276715883	adults
0.6276653415	secondary
0.6276512804	chinese
0.6276359691	resistant
0.6275983254	nk1
0.6275604499	weakness
0.6275345010	mptp
0.6274953905	analgesic
0.6273975723	morphine
0.6273769375	urticaria
0.6273626569	malformations
0.6273513252	trough
0.6272367855	reversal
0.6272067648	disturbances
0.6267949931	serial
0.6267598457	reversible
0.6267471626	delay
0.6267471626	minimum
0.6266081931	assessment
0.6265510416	lipid
0.6264784172	stage
0.6264228434	cholestatic
0.6263949834	behaviour
0.6263833929	line
0.6263408056	invasive
0.6263187414	stopping
0.6262273460	delayed
0.6261577073	tacrolimus
0.6261556461	recreational
0.6261394760	mu
0.6260655248	randomized
0.6259810969	ambulatory
0.6259515678	antithyroid
0.6259105586	combined
0.6259083441	bladder
0.6258886295	infants
0.6258588667	nephrotoxic
0.6254524889	tacrine
0.6254524889	clentiazem
0.6254444884	albino
0.6254391450	iu
0.6253901022	membrane
0.6253228899	risks
0.6252515100	molecular
0.6250967267	evaluation
0.6248445294	base
0.6248173450	asthma
0.6248173450	dystonia
0.6246992540	cyclic
0.6246709134	syndromes
0.6246709134	abnormality
0.6246709134	cytotoxic
0.6246627386	ko
0.6246627386	gad
0.6246627386	td
0.6246627386	thp
0.6245425692	numerous
0.6245425692	probability
0.6245425692	concerns
0.6245425692	normalization
0.6244957526	intracerebral
0.6244887837	cyclophosphamide
0.6243624914	widespread
0.6243143942	prevention
0.6243014632	metastatic
0.6242713662	balb
0.6242673330	ed50
0.6242283334	cancer
0.6239863160	convulsions
0.6238973039	social
0.6238971545	mg kg p.o
0.6238881231	quantitative
0.6236358287	pallidotomy
0.6235916252	erectile
0.6235823977	sensation
0.6235823977	cardiotoxic
0.6235723600	intermediate
0.6235474280	rabbit
0.6235311648	experimental
0.6234679429	markers
0.6234241975	cd
0.6232260289	cisplatin
0.6232158427	glomerular
0.6231609112	se
0.6228838379	clear
0.6228349051	mtdna
0.6227469304	botox
0.6227115019	catheter
0.6226870791	hydrochloride
0.6226041205	anticoagulant
0.6224540646	preliminary
0.6224041704	anticonvulsant
0.6223841489	pharmacokinetics
0.6223841489	dizziness
0.6223017672	nephrosis
0.6222971416	sudden
0.6221525428	dexrazoxane
0.6221525428	etoricoxib
0.6219832566	wall
0.6219297676	histologic
0.6219031118	virus
0.6218099016	muscular
0.6218089166	generation
0.6217216311	centrally
0.6216304959	view
0.6216227135	muscles
0.6215431028	early
0.6214664705	aneurysm
0.6214051954	serotonin
0.6212379511	autonomic
0.6212214529	ulcers
0.6211906963	summary
0.6210075484	graves
0.6209106544	predictive
0.6207963141	oab
0.6206773138	concomitant
0.6205997310	clinic
0.6205540291	regurgitation
0.6203945764	calcification
0.6202539092	mood
0.6200420498	systolic
0.6199369995	seizure
0.6198333597	ccr2
0.6198283982	wave
0.6198283982	ventilation
0.6198227255	low dose
0.6197117852	frequencies
0.6197020525	impact
0.6196176055	etiology
0.6196176055	anaesthetic
0.6196176055	components
0.6195748283	apical
0.6195685030	affinity
0.6195666166	characteristic
0.6194058731	subjects
0.6193721605	necrotizing
0.6193721605	electrolyte
0.6192364606	bile
0.6192320598	foot
0.6191737122	dosage
0.6191002641	pressures
0.6191002641	distal
0.6190839224	sd rats
0.6190307870	deprivation
0.6189284704	major
0.6189082717	hospitalized
0.6188985310	examination
0.6188893399	hyperactivity
0.6188137431	zidovudine
0.6187940224	pathways
0.6187846292	thrombocytopenia
0.6186180471	conduction
0.6186082965	accumulation
0.6185005191	nervous system
0.6184704733	space
0.6182701220	diabetes
0.6182273719	tuberculosis
0.6181672672	dl
0.6180647011	polyuria
0.6180387895	high risk
0.6180351273	disorders
0.6179770038	methylprednisolone
0.6177343563	arrhythmias
0.6177341721	hypercalcemia
0.6177295882	clonazepam
0.6177295882	localized
0.6176954514	muscle
0.6176557089	prominent
0.6176557089	fourth
0.6176464170	neuronal
0.6175676972	peptide
0.6175676972	intoxication
0.6175185162	emergency
0.6175151604	adequate
0.6173693876	unlike
0.6173693876	haematological
0.6170711821	les
0.6169896722	routine
0.6169433809	liver
0.6168475923	japanese
0.6168253437	aspartate
0.6167110587	corticosteroid
0.6167110587	culture
0.6165704130	disability
0.6165370495	tachyarrhythmias
0.6163424173	blood pressure and heart rate
0.6161564867	ci
0.6160526904	randomised
0.6158317528	aura
0.6157544145	intravascular
0.6155580784	hydroxylase
0.6154974707	women
0.6153443236	arrhythmia
0.6152097098	variability
0.6151058426	department
0.6150810876	words
0.6150751396	pulmonary
0.6150251007	steroid
0.6149420251	association
0.6149392207	progressive
0.6149123827	oncology
0.6148928413	muscarinic
0.6148896638	circulation
0.6148896638	temperature
0.6148623084	hemorrhagic
0.6147993809	psychosis
0.6147176040	respiratory
0.6146067282	transporter
0.6145402705	treat
0.6144774482	ca1
0.6143811074	delivery
0.6143083317	strategies
0.6143083317	monitor
0.6143083317	concern
0.6142733324	late
0.6140079774	potentials
0.6139629552	convulsant
0.6139560890	electrocardiographic
0.6138234044	medical
0.6137670591	depressive
0.6137162907	nx
0.6136217469	reflex
0.6135827873	microscopic
0.6135827873	beginning
0.6135725409	selectively
0.6135609844	efficacy
0.6135102103	tract
0.6135102103	aorta
0.6135091385	preclinical
0.6134521845	dba
0.6134260925	viral
0.6133785376	relative
0.6133713771	search
0.6132203111	correlation
0.6132146925	obstructive
0.6130806170	attenuated
0.6130480532	mm
0.6129711145	rigidity
0.6127787385	paracetamol
0.6125405618	penile
0.6124839181	mass
0.6124742837	adverse effect
0.6124639794	mg kg body weight
0.6124576762	convulsive
0.6124514272	natriuretic
0.6124506228	central
0.6123628696	significantly reduced
0.6123448831	airway
0.6121985744	bundle
0.6121483122	minor
0.6121483122	individual
0.6120178339	releasing
0.6119597304	lupus
0.6119478787	antibody
0.6119343143	isoflurane
0.6118487023	infections
0.6118369177	septal
0.6117339608	vasoactive
0.6117339608	intense
0.6116018292	acc
0.6115618197	earlier
0.6115412597	reference
0.6115412597	deficiency
0.6114430494	rizatriptan
0.6114080211	haemorrhage
0.6113802154	d3
0.6113276146	matrix
0.6113015803	papillary
0.6113008337	thrombin
0.6111917276	sgk1
0.6111254615	abuse
0.6110819754	antagonists
0.6110790167	utility
0.6110790167	continuously
0.6110790167	physiological
0.6110790167	controlling
0.6110168670	areas
0.6109671740	axonal
0.6106972743	laser
0.6106879397	lesion
0.6106863397	comparative
0.6106813492	consumption
0.6105276254	c57bl 6
0.6105267846	slow
0.6104224609	drop
0.6103302888	radiation
0.6102648180	future
0.6101833548	nephrotic
0.6100566158	regular
0.6098440276	point
0.6097299291	sevoflurane
0.6095562833	reactive oxygen
0.6094866403	nephrogenic
0.6094174447	inbred
0.6094174447	ischaemic
0.6094174447	targeting
0.6094174447	neutrophil
0.6094174447	questionnaire
0.6093111833	spontaneously
0.6092332719	blockers
0.6091621237	antihypertensive
0.6090285239	final
0.6090122382	safety
0.6089970924	ctni
0.6089830323	ischemia
0.6089770462	acidosis
0.6087986107	proliferation
0.6087855621	newborn
0.6087646900	hepatotoxicity
0.6087258871	neuropathy
0.6086828569	real
0.6081964267	blocker
0.6081462353	january
0.6081306909	bilateral
0.6080419089	interventions
0.6080265996	deficits
0.6078584659	striatal
0.6077870471	laboratory
0.6076657366	infiltration
0.6073139541	dystrophy
0.6073139541	bypass
0.6073139541	nystagmus
0.6072413389	adrenergic
0.6071846169	microscopy
0.6071568058	transaminase
0.6069879278	mk
0.6069782771	vasospasm
0.6068745145	knockout
0.6068506712	diffuse
0.6067778395	atrioventricular
0.6067761986	agonists
0.6067433669	subcutaneous
0.6067420124	induced cystitis
0.6066687031	node
0.6066687031	3,4
0.6066378894	cortisol
0.6065633647	diastolic
0.6065285709	content
0.6065115969	tone
0.6064597732	lead
0.6062727184	end
0.6062693483	lung
0.6062511834	strategy
0.6062385563	male
0.6062184418	optical
0.6061927645	cohort
0.6061109185	valve
0.6061105899	problems
0.6060986624	hemoglobin
0.6060385738	acetylcholine
0.6059883973	water
0.6059651732	care
0.6057948768	rash
0.6057779550	double blind study
0.6057492648	locomotor
0.6057228107	death
0.6057212056	arterial
0.6056280086	biopsies
0.6055716756	movement
0.6055716756	vision
0.6055716756	retinal
0.6055518411	sustained
0.6054500069	creatine
0.6054359852	simultaneously
0.6053623496	ninety
0.6052681226	average
0.6051875440	gallbladder
0.6051366088	mutants
0.6051257798	home
0.6050365486	functional
0.6049838043	ii
0.6049595258	oil
0.6049595258	dry
0.6048880886	form
0.6048526902	anesthetics
0.6047806424	susceptibility
0.6047688723	biliary
0.6046700052	light
0.6045818636	drinking
0.6044707539	dietary
0.6043605894	malignant
0.6041854464	lymphoma
0.6041412989	frontal
0.6040868684	cardiomyopathy
0.6039780233	inferior
0.6039347485	fasciculation
0.6039103091	replacement
0.6038942216	resistance
0.6037799865	iodixanol
0.6037740058	tests
0.6037727048	med
0.6037132394	oxygen
0.6036937869	imaging
0.6036280598	pathological
0.6036138809	fulminant
0.6034588513	basis
0.6034547148	triglyceride
0.6034547148	micturition
0.6034547148	iohexol
0.6033174483	free
0.6033038998	vessels
0.6030451492	accelerated
0.6030451492	natural
0.6030437303	recipients
0.6030222255	antiepileptic
0.6029844046	alkaline
0.6029744877	additionally
0.6029694670	middle
0.6029208579	growth
0.6028692937	hyperplasia
0.6027828830	trial
0.6027494239	users
0.6027322871	conventional
0.6026545747	facial
0.6024500663	glutathione
0.6024498621	binding
0.6024460313	sinoatrial
0.6023784716	mmol
0.6023309191	fluid
0.6023278450	visual
0.6021302585	dependence
0.6020864505	alanine
0.6020551900	bacterial
0.6018652622	4 aminopyridine
0.6018620033	starting
0.6017923978	june
0.6017655236	acquired
0.6017561036	ganglia
0.6016361212	seventy
0.6014956293	extrapyramidal
0.6014540606	subsequently
0.6014307721	living
0.6014280996	factors
0.6014163529	output
0.6013864535	myocardial
0.6013603887	dyskinesias
0.6013567591	nephropathy
0.6013401947	galactose
0.6012972866	nerve
0.6012404806	tam
0.6011303029	sinus
0.6010671382	vomiting
0.6010353539	internal
0.6008938569	shock
0.6007164754	ctnt
0.6007017305	compound
0.6006845867	measures
0.6006403836	pregnancy
0.6006086510	oxidative
0.6005834211	substance
0.6004915432	adverse
0.6004725428	oxidase
0.6004004238	mg kg ip
0.6003314864	lethal
0.6002851400	iu l
0.6002761320	fifty
0.6002691091	anterior
0.6001686427	open
0.6001520585	carcinoma
0.6001356933	phosphatase
0.6000759510	obstruction
0.6000144243	ephedrine
0.5999410809	vein
0.5999301156	maximal
0.5999053093	common
0.5998271762	amantadine
0.5997213399	procedure
0.5997151476	collection
0.5995461742	experience
0.5995424953	critical
0.5995234639	count
0.5995234639	renin
0.5995166943	nucleus
0.5993720131	magnitude
0.5992783837	essential
0.5992638834	simultaneous
0.5990832220	edema
0.5990536144	purpose
0.5989692253	complications
0.5989621587	anesthetized
0.5989488813	acidic
0.5989039889	material
0.5988582266	ntr
0.5985890419	younger
0.5985061915	comparing
0.5984897910	uveitis
0.5984897910	overflow
0.5984742420	atrophy
0.5984327222	progression
0.5983961123	forestomach
0.5983163091	treated animals
0.5982409140	peak
0.5981699957	lactate
0.5980872902	methyl
0.5980275854	glycopyrrolate
0.5980023311	anesthetic
0.5979867903	calcineurin
0.5979835119	lasting
0.5979731344	sulphasalazine
0.5979731344	hilar
0.5979731344	alternation
0.5978933294	aggressive
0.5977640742	mouth
0.5977425465	tyrosine
0.5976655372	protective
0.5974127969	db
0.5974127969	word
0.5973511218	morbidity
0.5973295425	apap
0.5972064006	infected
0.5971264820	cardiovascular
0.5969449578	arteries
0.5968205424	postoperative
0.5967994999	syndrome
0.5967560851	meq l
0.5967441141	urea
0.5967173367	diazepam
0.5965898132	subjective
0.5965590539	graft
0.5964967440	surface
0.5964477688	aim
0.5963842308	tachycardia
0.5963533960	evoked
0.5963220331	cocaine
0.5963025504	medium
0.5962814620	newly
0.5961942788	neurological
0.5960120693	deterioration
0.5959834672	episode
0.5958283173	frequent
0.5957700310	thirteen
0.5956987192	cirrhosis
0.5956033245	behavior
0.5953573833	active
0.5952391425	blocked
0.5952281859	ingestion
0.5952276335	occlusion
0.5952075976	pain
0.5951011434	nerves
0.5949653998	att
0.5949653998	cs
0.5949653998	ax
0.5949246559	inhibitory
0.5948575829	terminal
0.5947948883	human
0.5946378762	interaction
0.5946311086	hormone
0.5945881530	authors
0.5945686275	urine
0.5945531272	cox 2
0.5944903721	reactions
0.5944489528	birth
0.5944265031	adult
0.5943717878	young
0.5942837529	attack
0.5942827231	characteristics
0.5942420174	linked
0.5939297301	radical
0.5939297301	dehydrogenase
0.5939261688	valvular
0.5938957138	stimulating
0.5938704745	added
0.5938704745	intracellular
0.5938704745	irreversible
0.5938704106	significant difference
0.5937406639	size
0.5937048645	caution
0.5936457283	patterns
0.5936238832	transmission
0.5936194833	discussion
0.5934843795	hepatitis
0.5934746588	marker
0.5933760230	polydrug
0.5932902497	physicians
0.5931640607	complex
0.5930405685	production
0.5930259873	phenomenon
0.5928710291	positive
0.5928398702	basement
0.5927936799	explore
0.5927470166	male sprague dawley
0.5927253053	pretreated
0.5927197509	eighty
0.5926109656	superior
0.5925532732	plasma
0.5925293387	states
0.5925075969	swiss
0.5925075969	november
0.5924615142	cerebrospinal
0.5924586108	careful
0.5924468122	intravenous
0.5924002445	regression
0.5923920244	elevations
0.5922955673	world
0.5922564789	subunits
0.5922089939	mug
0.5922030265	sulphate
0.5921109281	exercise
0.5920240758	materials
0.5919613944	previous studies
0.5919256369	segment
0.5919256369	interactions
0.5918816875	findings
0.5918168161	clinicians
0.5917932306	leukocyturia
0.5917932306	dilevalol
0.5917809401	plasma concentration
0.5917558435	acts
0.5917507849	appetite
0.5917393147	withdrawal
0.5917111069	component
0.5917012427	taking
0.5916675143	anemia
0.5916465278	region
0.5913492293	hypothesis
0.5912887212	adrenoceptor
0.5912868213	outcomes
0.5912826078	tubular
0.5912081114	ovarian
0.5911761154	date
0.5910723969	functions
0.5909159644	enos
0.5909059059	organ
0.5908969559	oral
0.5908296429	ratio
0.5906760927	alternative
0.5906540235	blood
0.5906308187	length
0.5906288701	cyclosporin
0.5905360585	cytochrome
0.5904931095	similarly
0.5903647709	man
0.5902921836	proteins
0.5901773678	describes
0.5901294482	trihexyphenidyl
0.5901294482	hematoma
0.5901294482	alpha2
0.5901294482	rifampin
0.5901294482	fluvoxamine
0.5901294482	angiotensinogen
0.5900308331	coma
0.5900297096	autoimmune
0.5899941332	flestolol
0.5898851449	unchanged
0.5898405996	inos
0.5898269819	heart
0.5897948206	neck
0.5896302583	paradoxical
0.5895529674	interstitial
0.5895317320	alpha
0.5895250485	sodium
0.5894388220	nm
0.5894364042	puromycin aminonucleoside induced
0.5894229137	sufficient
0.5893887450	coenzyme
0.5892828039	finally
0.5891081446	distribution
0.5889244288	patient presented
0.5889169238	elevation
0.5888786292	data
0.5888247241	degeneration
0.5888029475	fourteen
0.5887593831	subgroups
0.5887593831	autopsy
0.5887593831	prompt
0.5887593831	inpatient
0.5887593831	improving
0.5887593831	concomitantly
0.5887593831	predominantly
0.5885907935	december
0.5885545262	inflammatory
0.5884836888	rtms
0.5884200463	beta1
0.5883859325	reductions
0.5883310236	atrial
0.5883081308	total
0.5882836698	bipolar
0.5881906697	mpo
0.5880811621	types
0.5880242662	selegiline
0.5880242662	asenapine
0.5880242662	coniine
0.5879950587	years of age
0.5879865858	admitted
0.5879048245	randomly assigned to
0.5877339487	creatinine
0.5875131023	s.c
0.5874644916	polymerase
0.5873968154	number
0.5873492534	micromol
0.5873260948	pre
0.5872737106	double
0.5871797332	secretion
0.5871635326	depletion
0.5870597435	coronary
0.5869864557	series
0.5868853197	modulation
0.5867089167	fold
0.5867031665	degree
0.5865928033	species
0.5864800837	partial
0.5864116007	reactive
0.5864020766	effectiveness
0.5862231180	cab
0.5862231180	riha
0.5861473870	sterile
0.5861473870	netilmicin
0.5861473870	rocuronium
0.5861473870	encoded
0.5861473870	deferoxamine
0.5861473870	lamina
0.5861275081	serum
0.5861101012	hearing
0.5860745711	lesioned
0.5860745711	mm3
0.5860745711	corticosterone
0.5860252776	chronic
0.5860132269	p.o
0.5859706873	men
0.5859629305	noradrenaline
0.5858857252	animals
0.5857379914	amino
0.5857358552	volunteers
0.5856527310	val
0.5856527310	rls
0.5856527310	pregs
0.5856370736	metabolism
0.5855190958	prostate
0.5854875211	dopamine
0.5853832312	application
0.5852943085	risk
0.5851812503	carbon
0.5851744472	kinase
0.5851182527	tomography
0.5851175827	tissue
0.5850847824	clozapine
0.5850744044	mumol
0.5850146079	mrp2
0.5848339032	extent
0.5847501447	examinations
0.5847501447	return
0.5845667657	psychotic
0.5844684192	defined
0.5844662788	experiments
0.5844343651	epilepsy
0.5843637232	apparent
0.5843577168	barrier
0.5843537649	tumor
0.5842892293	schizophrenia
0.5842787004	staining
0.5841932903	duct
0.5841022950	cta
0.5841022950	vcm
0.5840560384	potent
0.5840058198	intensive
0.5839439060	review
0.5837893304	preference
0.5837893304	glycine
0.5837893304	inhaled
0.5837865697	kappab
0.5837865697	pregnancies
0.5837865697	loaded
0.5837865697	erythrocytes
0.5837865697	sertraline
0.5837865697	aprotinin
0.5836784587	infusions
0.5835042764	epithelial
0.5833286562	rare
0.5832553967	maintenance
0.5832293498	significantly higher
0.5831587065	i.c.v
0.5831169549	pharmacological
0.5830828653	deaths
0.5830774966	disruption
0.5829866700	estimate
0.5828987812	rise
0.5828400018	single
0.5827683231	temporal
0.5827390900	mazindol
0.5827040219	incidence
0.5826842847	rationale
0.5826797552	motor
0.5826538017	consecutive
0.5826272155	rodents
0.5825186612	vocal
0.5825042573	records
0.5824658699	involvement
0.5823139855	n methyl d aspartate
0.5822689083	reduce
0.5821418240	identify
0.5820569643	movements
0.5820527179	induction
0.5819911372	patients in group
0.5819365700	smooth
0.5817909879	small
0.5817537400	dentate
0.5817054069	peripheral
0.5816503520	ischemic
0.5815522551	prolongation
0.5815145709	profile
0.5812625828	bowel
0.5812074646	nephritis
0.5811723343	generally
0.5810950038	calcium
0.5810838484	actions
0.5810826828	dilated
0.5809086212	systems
0.5808682285	sex
0.5808228691	pathway
0.5807702704	patients and methods
0.5807215388	courses
0.5805502225	girl
0.5805502225	manifestation
0.5805502225	existing
0.5804732521	detected
0.5803823184	post
0.5803338597	gene
0.5803125105	kidney
0.5802657590	cross
0.5802421884	increases
0.5801756018	rating
0.5801073424	fatal
0.5800209134	gall
0.5799633877	pattern
0.5798380357	information
0.5797848364	pgp
0.5797841050	undergoing
0.5797694480	strong
0.5797133699	intensity
0.5796302331	cerebral
0.5795726891	randomized to receive
0.5794876037	plasticity
0.5794876037	chow
0.5794876037	anionic
0.5794100051	rhythm
0.5793902667	palsy
0.5793848994	pacemaker
0.5792291292	severe
0.5791940521	echocardiography
0.5790485341	striatum
0.5790485341	chloride
0.5789454595	immediately
0.5788454882	synthase
0.5787895488	frequency
0.5787700218	suppression
0.5786959011	nausea
0.5786177807	ocs
0.5786177807	glepp1
0.5786177807	scr
0.5786067160	segments
0.5786067160	cost
0.5785266968	mtor
0.5784925200	cortex
0.5784380954	divided
0.5784148283	wistar
0.5783352724	lna
0.5782818530	ethanol
0.5782701804	test
0.5781187297	evaluable
0.5780590398	nonsteroidal
0.5780424655	nitrogen
0.5779234226	clonic
0.5778346390	arrest
0.5777987957	aims
0.5777932380	transplant
0.5777906632	materials and methods
0.5775790923	resolution
0.5775121501	biochemical
0.5774416937	repeated
0.5773345207	investigation
0.5772006398	compare
0.5771874108	based
0.5771030765	optic
0.5770705209	activities
0.5768142779	result
0.5767030852	acetate
0.5766564075	injections
0.5766431326	proportion
0.5764977698	solution
0.5763315931	large
0.5762442948	oestrogen
0.5762442948	tongue
0.5762442948	daunorubicin
0.5762442948	modifications
0.5762442948	survivors
0.5762397815	arthritis
0.5761798563	proteinuria
0.5761150423	randomly
0.5760555839	improve
0.5760212660	bid
0.5758000654	micrograms
0.5756996690	design
0.5755063502	implant
0.5755063502	transformation
0.5755063502	afferent
0.5755063502	astrocytes
0.5754150501	area
0.5752173732	importance
0.5750932950	operative
0.5750562283	ipsilateral
0.5750562283	mg.kg
0.5750562283	dp
0.5750562283	depleted
0.5750562283	lignocaine
0.5750562283	anuria
0.5750562283	pegylated
0.5750562283	medullary
0.5750562283	night
0.5750562283	opiate
0.5749372047	aldosterone
0.5747626933	decline
0.5747363927	pathophysiology
0.5746926396	monoher
0.5745285034	turnover
0.5744690299	hypertension
0.5744045119	relationship
0.5743585773	alterations
0.5743106366	dose reduction
0.5742899471	receive
0.5742684065	measurements
0.5742677416	renal toxicity
0.5741658680	pathogenesis
0.5741428553	chain
0.5741135640	hypotension
0.5740194445	recent
0.5739257325	end stage renal
0.5738863336	paper
0.5738863336	ranged
0.5736730809	times
0.5735628830	correlated
0.5734227573	lymphoblastic
0.5734215297	differ
0.5734215297	detection
0.5732659011	reports
0.5731870428	objectives
0.5731482258	microg
0.5730704752	statistical
0.5729310485	chest
0.5726184256	group
0.5725833561	abnormalities
0.5725352118	thirty
0.5722122571	transplantation
0.5721518760	fraction
0.5721039112	points
0.5718130412	undertaken
0.5717995522	group ii
0.5717385483	detect
0.5715670666	necrosis
0.5715074680	u l
0.5714836032	events
0.5714201769	avoid
0.5714201769	referred
0.5713661766	case
0.5713367014	returned
0.5712382635	beneficial
0.5712382635	percentage
0.5711765837	significant
0.5711745769	elevated
0.5711162930	discontinuation
0.5710598118	ouabain
0.5709702584	artery
0.5709202586	objective
0.5707379544	excretion
0.5706999463	corneal
0.5706536927	evidence
0.5705515381	acute
0.5705465968	humans
0.5705075162	contribution
0.5704918658	features
0.5703910342	escape
0.5703274639	postmenopausal
0.5703274639	predictors
0.5703165242	matter
0.5702707696	properties
0.5702507914	disorder
0.5701822737	label
0.5700673362	hemolytic
0.5700251220	inhibition
0.5700053339	manner
0.5699376230	stimulation
0.5698950827	recently
0.5698311074	widely
0.5697500032	cardiomyocytes
0.5697446202	patients
0.5696895364	studies
0.5696171309	cyclosporine
0.5694653119	cacl
0.5694561262	2a
0.5694309192	desire
0.5694309192	bicarbonate
0.5693719381	methods
0.5693253865	difference
0.5692452690	support
0.5691797125	inhibited
0.5691453288	hypothermia
0.5691453288	predominant
0.5691453288	confounding
0.5688949391	tolerated
0.5688729764	aimed
0.5686998064	days
0.5684331743	nra0160
0.5684082937	units
0.5683075122	meq
0.5682643984	controls
0.5681468079	similar
0.5681141190	episodes
0.5678964795	failure
0.5678196173	signs
0.5677152019	genes
0.5677049949	den
0.5676171020	neurotoxic
0.5674002214	produce
0.5673592422	percent
0.5672881040	breast
0.5672590322	marrow
0.5672400669	aminoglycoside
0.5671996726	positive cells
0.5671411243	ventricular
0.5669955823	antibiotic
0.5669492960	ability
0.5669486772	implicated
0.5668099169	media
0.5668099169	apoptotic
0.5667872786	designed
0.5666890847	deficient
0.5666890847	picrotoxin
0.5666382287	analysis
0.5665380228	channel
0.5664863049	regulation
0.5663697047	tardive
0.5663606287	erythema
0.5663515138	main
0.5661840125	left
0.5661211936	influence
0.5660415899	month
0.5657882199	model
0.5656677098	growth factor
0.5656640002	fully
0.5656640002	elicited
0.5656431908	site
0.5656362792	rapid
0.5654844612	outcome
0.5653742625	equal
0.5652164126	attributable
0.5651230754	examine
0.5650922592	efficacy and safety
0.5650916016	alkali
0.5648036888	thought
0.5647088718	dependently
0.5646334436	experiment
0.5645136453	gyrus
0.5644618873	doses
0.5644153539	develop
0.5643788717	clinical
0.5642225716	recovery
0.5642216035	hour
0.5641845519	bolus
0.5641389791	seizures
0.5640294408	setting
0.5639865737	seconds
0.5638957639	subsequent
0.5638951573	status
0.5638556670	north
0.5637206861	measurement
0.5636696036	abstract
0.5635194575	mortality
0.5634479905	pilot
0.5634426837	ph
0.5632207442	clearance
0.5631254797	microinjection
0.5631081272	velocity
0.5631081272	weighted
0.5631081272	contractility
0.5631081272	microgram
0.5628048825	agonist
0.5627804705	amphotericin
0.5626966579	fluorouracil
0.5625416891	limited
0.5624665837	elderly
0.5624144115	prevalence
0.5623497921	attributed
0.5623452539	preparations
0.5623452539	endogenous
0.5622485607	salt
0.5622010763	developing
0.5621980335	dopaminergic
0.5620506686	neonates
0.5620143000	involved
0.5617776534	initial
0.5615816126	microm
0.5615634684	investigate
0.5614628683	injury
0.5613714157	antagonist
0.5613394372	preceded
0.5609366383	injected
0.5606711122	event
0.5606168337	age
0.5606008975	female
0.5604386032	diagnosed
0.5603577184	layer
0.5603577184	signal
0.5601431554	evaluate
0.5601430882	variants
0.5601430882	lines
0.5601430882	locomotion
0.5601430882	ligands
0.5601430882	oxidant
0.5599388137	protein
0.5599032980	minimal
0.5598844936	reversed
0.5597744829	pentylenetetrazole
0.5597744829	antigens
0.5597744829	foci
0.5597744829	fractures
0.5597744829	ventral
0.5597744829	intracoronary
0.5597744829	abundance
0.5597744829	antioxidants
0.5597744829	naproxen
0.5597744829	irrigation
0.5597744829	contractions
0.5596000093	higher
0.5594974681	vitamin
0.5594505952	formation
0.5593059101	power
0.5593059101	globulin
0.5593059101	radiotherapy
0.5592573590	propranolol
0.5592491223	needed
0.5589403865	diameter
0.5588815414	commonly
0.5588606287	crack
0.5587603908	cardiac
0.5586886151	affected
0.5585880993	wk
0.5585156828	appearance
0.5580745837	cord
0.5580301455	impaired
0.5580098554	aware
0.5579356338	highest
0.5579356338	variables
0.5579037698	affect
0.5578089470	strains
0.5577486149	infection
0.5577434894	rejection
0.5577421155	factor
0.5576124788	dogs
0.5574649277	nmol
0.5570607904	statistically
0.5569023143	prior
0.5568121282	control animals
0.5567863989	boy
0.5567473285	toxic
0.5567138533	sensitive
0.5565519433	adjusted
0.5564000767	consisted
0.5563760142	brain
0.5562340950	severity
0.5561732633	pronounced
0.5561648165	inhibitors
0.5559846829	previously
0.5557692320	daily dose
0.5556557689	inducible
0.5556557689	discharge
0.5556557689	correlates
0.5556557689	reporting
0.5555311866	challenge
0.5554884164	untreated
0.5553666540	mild
0.5552521356	amounts
0.5551640826	concurrent
0.5551598133	literature
0.5551538726	class
0.5549637691	consequence
0.5546813553	induced hypotension
0.5546254797	uremic
0.5546083637	reuptake
0.5545472800	cultures
0.5545472800	perfused
0.5545198753	achieve
0.5543382045	extract
0.5542518415	failed
0.5542141501	contrast
0.5541205496	mechanisms
0.5539072520	lymphocyte
0.5539072520	antiinflammatory
0.5539072520	fell
0.5539072520	ethyl
0.5539072520	room
0.5539072520	analgesics
0.5539072520	trained
0.5539072520	scored
0.5539072520	postsynaptic
0.5537685429	increased
0.5536833258	order
0.5536306934	patient's
0.5536254797	glyceryl
0.5536254797	means
0.5536098327	donor
0.5535859327	control
0.5535453748	carriers
0.5534392322	regimen
0.5533910448	initially
0.5533910448	mixed
0.5533822841	accompanied
0.5532132679	stress
0.5531457562	lozenge
0.5530659506	fall
0.5530535047	groups
0.5529938430	characterized
0.5529896708	exposed
0.5529379095	leads
0.5528154186	jj
0.5527600256	procedures
0.5527095456	discharged
0.5527095456	excitability
0.5527095456	preterm
0.5527095456	pacing
0.5527095456	face
0.5527095456	beating
0.5527095456	interference
0.5525243386	appears
0.5523502547	potential
0.5520291249	lowering
0.5519557726	supplementation
0.5519557726	combinations
0.5519557726	antibiotics
0.5518397042	dementia
0.5518326371	reaction
0.5517816237	study
0.5517153879	aged
0.5516608333	long
0.5516446733	aminotransferase
0.5516446733	monotherapy
0.5516196822	retrospective study
0.5515130923	therapeutic
0.5513118442	lower
0.5512752022	enzyme
0.5510306996	investigations
0.5510306996	cellular
0.5510306996	relevant
0.5510204897	separate
0.5509547646	mmhg
0.5508598423	surgery
0.5508195058	combination
0.5508051262	curve
0.5508051262	close
0.5506348258	cows
0.5506043633	history
0.5504241956	high
0.5504200653	neurons
0.5503063017	propofol
0.5502805158	volume
0.5502493070	inhibitor
0.5499550812	highly
0.5497193393	relapsed
0.5497193393	gestation
0.5497193393	step
0.5496716792	reducing
0.5494245916	suggestive
0.5494245916	regard
0.5494245916	conjunction
0.5493989052	response
0.5492367475	amplitude
0.5491875051	complication
0.5491610458	training
0.5489852502	important
0.5488866394	action
0.5488487629	increasing
0.5488357318	symptoms
0.5486234864	low
0.5484720865	advanced
0.5484244224	cells
0.5482908168	impairment
0.5482699241	tricyclic
0.5482219123	decrease
0.5481734923	upregulation
0.5481061350	led
0.5480009055	antioxidant
0.5479676852	i.v
0.5479553004	acid
0.5476412583	cardiopulmonary
0.5474772110	healthy
0.5473854862	vehicle
0.5473023209	glomerulonephritis
0.5472725943	responsiveness
0.5472725943	lethality
0.5470458019	admission
0.5468903760	tasks
0.5468903760	contractile
0.5468903760	fractional
0.5468903760	benzodiazepines
0.5468903760	abusers
0.5465387619	presentation
0.5463252563	altered
0.5463099842	patient
0.5462310597	consistent
0.5461264761	benzodiazepine
0.5461264761	neurotransmitter
0.5461264761	shortening
0.5461264761	transplanted
0.5461264761	substrate
0.5461264761	targeted
0.5461264761	anthracycline
0.5461264761	psychological
0.5460091459	established
0.5458790582	prolonged
0.5458116959	appeared
0.5457810021	saline
0.5455794870	activation
0.5455582487	lobe
0.5453581199	infarction
0.5452039729	interval
0.5451211981	disease
0.5450104439	dopa
0.5449736810	enhanced
0.5447796377	product
0.5447652005	mg
0.5446275200	occurrence
0.5445861143	aminonucleoside
0.5445523692	specific
0.5445224842	avoidance
0.5444523904	maximum
0.5444154848	woman
0.5443688951	independent
0.5443253555	divided into
0.5443175703	rapamycin
0.5443167050	i.p
0.5440695881	results
0.5440607160	confirmed
0.5438902170	sample
0.5438740563	intake
0.5438507231	predict
0.5438507231	limit
0.5438003636	models
0.5436994041	drug
0.5434245916	immunodeficiency
0.5434135911	method
0.5433350974	renal
0.5433350009	metabolite
0.5433347408	weeks
0.5429763527	hours
0.5427442369	type
0.5425378464	p75
0.5425378464	cinacalcet
0.5424245916	numbers
0.5424069798	individuals
0.5422857027	acuity
0.5419531590	tested
0.5417619709	retention
0.5416384058	reviewed
0.5415113579	rats
0.5413791794	cases
0.5412988116	minute
0.5412857151	fluctuations
0.5411362289	induce
0.5411303907	diagnosis
0.5409787366	determine
0.5409251418	exposure
0.5408909125	release
0.5406151044	counts
0.5405023429	damage
0.5404897785	minutes
0.5404660943	vitro
0.5404088399	reabsorption
0.5404088399	thickness
0.5404088399	brains
0.5404088399	hexamethonium
0.5404088399	speed
0.5404088399	osmolality
0.5404088399	myocytes
0.5404088399	antipsychotics
0.5403978284	addition
0.5399012361	remained
0.5397963461	approximately
0.5396083240	safety and efficacy
0.5395400713	reduced
0.5394902411	experienced
0.5393379958	technique
0.5393133772	bilirubin
0.5392420579	concentrations
0.5391189339	range
0.5389639642	undergone
0.5389639642	limbs
0.5389639642	implanted
0.5389639642	bilaterally
0.5388950788	ml
0.5388277565	block
0.5385609414	conducted
0.5385486458	placebo
0.5384656657	l sotalol
0.5383926487	mice
0.5380640563	prevented
0.5379983092	mediated
0.5377277015	medications
0.5373866803	loss
0.5371722100	frequently
0.5370836656	shortly
0.5370281351	parkinsonian
0.5369901372	differences
0.5369578726	dependent
0.5368641320	identified
0.5367403475	yr
0.5363073065	murine
0.5363073065	session
0.5363073065	lymphocytes
0.5363073065	residual
0.5363073065	moving
0.5363073065	membranes
0.5361933379	body
0.5360702940	suggested
0.5360452829	marrow transplantation
0.5357292420	noted
0.5356745351	cancers
0.5356414315	greater
0.5351351327	change
0.5350196971	vivo
0.5343961104	pressure
0.5341005336	moderate to severe
0.5339675485	ratings
0.5339675485	immunosuppression
0.5339675485	functioning
0.5339675485	neurotransmission
0.5339675485	nuclei
0.5339675485	paradigm
0.5337197465	agent
0.5332121295	initiation
0.5332023021	conclusions
0.5331503237	prevent
0.5331077769	expression
0.5330079818	fibrosis
0.5329901836	tissues
0.5329870154	months
0.5328894280	effective
0.5327281101	contributes
0.5327281101	mellitus
0.5327087050	required
0.5325230902	receptors
0.5323272255	diet
0.5323252649	dysfunction
0.5322677071	week
0.5321890482	restricted
0.5321430720	start
0.5320929290	pod
0.5320566830	onset
0.5319890576	stimulant
0.5319890576	excess
0.5319890576	females
0.5316384881	background
0.5314500310	fed
0.5314302026	loading
0.5314302026	potency
0.5314302026	myocardium
0.5314302026	therapies
0.5314302026	chemotherapeutic
0.5314302026	institution
0.5314302026	pathology
0.5314302026	lowered
0.5314302026	diminished
0.5314302026	generated
0.5313914863	induced psychosis
0.5313355662	filtration
0.5312867501	dog
0.5312867501	surveillance
0.5312867501	hemodialysis
0.5312867501	born
0.5312867501	stimuli
0.5312867501	repeatedly
0.5310302767	leading
0.5308995207	comparison
0.5307290930	weight
0.5307008603	agents
0.5302640394	resulted
0.5300441693	microangiopathy
0.5299920964	peroxidation
0.5297911232	presented
0.5296611546	infusion
0.5295475155	intervals
0.5294692251	duration
0.5289643776	rates
0.5289294539	beta
0.5286410707	blockade
0.5285797895	measured
0.5285135226	pressor
0.5285082294	plasma concentrations
0.5284870463	report
0.5284574486	anticoagulation
0.5283931403	hearts
0.5283791618	min
0.5283741153	strain
0.5283741153	unilateral
0.5283741153	uptake
0.5283245244	intestinal
0.5283245244	cycles
0.5282577718	excluded
0.5282410947	mouse
0.5281972233	variable
0.5281972233	presumed
0.5281972233	beats
0.5281972233	stimulated
0.5279490137	development
0.5279350617	assess
0.5279169640	epithelium
0.5279169640	normotensive
0.5279169640	altering
0.5279169640	subset
0.5279169640	curves
0.5279169640	indices
0.5279169640	rose
0.5279169640	e.g
0.5279169640	contained
0.5279169640	enhancing
0.5279169640	cultured
0.5279169640	analog
0.5279169640	phenotype
0.5279169640	deposits
0.5278913036	potentiated
0.5278913036	protect
0.5278913036	adjustment
0.5278913036	continue
0.5278913036	degrees
0.5278913036	disturbance
0.5278913036	smaller
0.5274220843	dose dependent manner
0.5272574534	resulting
0.5270887796	intraperitoneally
0.5269886173	extrapyramidal side
0.5264565613	incidence and severity
0.5262361706	sites
0.5260487930	kg
0.5260212965	treatment
0.5259499531	mechanism
0.5258569982	passive
0.5257283080	subcutaneously
0.5254317351	prospective study
0.5253133076	compounds
0.5252549759	examined
0.5250310148	refractory
0.5250273977	condition
0.5248472826	regimens
0.5248140487	recording
0.5248140487	restored
0.5248140487	enhance
0.5248140487	analysed
0.5248140487	ameliorated
0.5247963869	obtained
0.5244144003	assessed
0.5241714797	increase
0.5241498829	published
0.5239622410	drugs
0.5239584940	dose
0.5237890889	receptor
0.5233009138	poorly
0.5233009138	presents
0.5233009138	act
0.5233009138	rest
0.5233009138	slight
0.5233009138	formed
0.5233009138	gender
0.5233009138	safely
0.5233009138	lacking
0.5233009138	removed
0.5233009138	structures
0.5233009138	ineffective
0.5233009138	greatest
0.5233009138	exerts
0.5227944824	blind
0.5227227783	l name
0.5226191305	shown
0.5225617774	reported
0.5225393333	toxicity
0.5221215725	protected
0.5221215725	mediate
0.5221215725	enhances
0.5221215725	lasted
0.5221215725	schizophrenic
0.5221215725	began
0.5220637934	blocking
0.5220279154	evaluated
0.5219922517	killed
0.5219922517	benefits
0.5219922517	alteration
0.5219922517	localization
0.5219922517	mother
0.5219922517	employed
0.5219922517	dosages
0.5217473397	cell
0.5216603373	relapse
0.5215191819	rate
0.5214017624	origin
0.5213651878	activity
0.5213454840	considered
0.5213053114	terms
0.5208053114	ejection
0.5205154996	conclusion
0.5200089551	confirm
0.5200089551	cytoplasmic
0.5200089551	compensatory
0.5200089551	inhibits
0.5199333856	years
0.5199117693	intrathecal
0.5198763943	fixed
0.5197309796	determined
0.5196920087	monitoring
0.5196774862	torsade
0.5194231556	produced
0.5186937535	receiving
0.5186774862	aplastic
0.5186714828	male wistar
0.5185597049	stable
0.5184530201	cessation
0.5178251594	lack
0.5174905945	effect
0.5171720853	choice
0.5171720853	effectively
0.5171720853	represents
0.5171720853	correlate
0.5171720853	carefully
0.5171720853	contributed
0.5169628984	respect
0.5168149101	present
0.5166875713	decreased
0.5162379601	control groups
0.5158919607	usage
0.5158919607	modulate
0.5158919607	unaffected
0.5158919607	sections
0.5158919607	consciousness
0.5158919607	persons
0.5158919607	tablets
0.5158919607	profiles
0.5158919607	hospitalization
0.5158919607	stability
0.5157858760	injection
0.5155495940	included
0.5155332218	level
0.5155145553	prescribed
0.5152582278	concentration
0.5152427977	threshold
0.5151744189	follow up period
0.5150503387	analgesia
0.5150056115	protects
0.5150056115	consequences
0.5150056115	hypothesized
0.5150056115	proven
0.5150056115	discuss
0.5150056115	fact
0.5150056115	raised
0.5148887861	proposed
0.5148887861	sequelae
0.5148887861	decreasing
0.5148887861	profound
0.5148402792	suggest
0.5143858054	weekly
0.5137483055	exhibit
0.5137483055	acetyl
0.5137483055	reach
0.5137483055	blocks
0.5137483055	hospitals
0.5137483055	success
0.5137483055	classic
0.5137483055	met
0.5137483055	quantify
0.5137483055	blinded
0.5137483055	preserved
0.5137483055	corrected
0.5137483055	expressed
0.5137483055	needle
0.5137483055	gradual
0.5137483055	subgroup
0.5137483055	occasions
0.5136494866	catecholamines
0.5136494866	unique
0.5136494866	measuring
0.5136494866	efficacious
0.5136494866	prescribing
0.5136494866	equally
0.5136494866	expected
0.5136494866	modified
0.5136494866	involve
0.5134835005	streptozotocin induced
0.5132550821	intact
0.5132550821	schedule
0.5131683290	performed
0.5130220553	significantly
0.5129565644	occurred
0.5129359826	function
0.5128291084	antagonized
0.5128291084	males
0.5127904270	responsible
0.5127648001	i.e
0.5127648001	infant
0.5124993918	hand
0.5122620115	analogue
0.5122487648	caused
0.5120335430	contribute
0.5118158078	permanent
0.5117055985	investigated
0.5116520049	metabolites
0.5116240274	period
0.5113718797	m2 d
0.5109892142	stem
0.5109815883	enzymes
0.5109793358	fibrillation
0.5109371328	hypotensive
0.5109302917	infused
0.5109302917	larger
0.5109302917	identical
0.5105504696	underlying
0.5105334313	rat
0.5105151148	insufficiency
0.5102144806	calculated
0.5101714880	regions
0.5097824923	role
0.5093970615	poor
0.5093970615	preventing
0.5089513893	puromycin
0.5084727911	influenced
0.5084727911	experiences
0.5084727911	forms
0.5084727911	discontinuing
0.5084727911	attenuates
0.5084727911	avoided
0.5084727911	focus
0.5084727911	rarely
0.5084727911	limits
0.5084727911	wide
0.5084727911	attenuate
0.5084727911	putative
0.5084727911	postulated
0.5084727911	encountered
0.5084727911	techniques
0.5084727911	independently
0.5084727911	responded
0.5084727911	substances
0.5084727911	populations
0.5084727911	lesser
0.5084727911	severely
0.5084727911	restoration
0.5084294928	reduction
0.5081846271	parameters
0.5081774518	protocol
0.5080497882	observed
0.5076387360	related
0.5076286984	documented
0.5075335927	probable
0.5075335927	difficult
0.5075292297	follow
0.5071339341	suppressed
0.5071288747	dosing
0.5069295137	sensory
0.5065477373	effects
0.5063838909	orally
0.5059942766	returned to normal
0.5057425646	angiotensin
0.5055989288	subject
0.5055869494	treated
0.5053456543	respective
0.5053456543	slowing
0.5053456543	benign
0.5053456543	trans
0.5053456543	fashion
0.5053456543	acutely
0.5053456543	structurally
0.5053456543	account
0.5053456543	delivered
0.5053456543	easily
0.5053456543	experimentally
0.5053456543	option
0.5053456543	sought
0.5053456543	computerized
0.5053456543	respond
0.5053456543	shortened
0.5053456543	explain
0.5053456543	involves
0.5053456543	aspects
0.5053456543	preexisting
0.5053456543	mentioned
0.5053456543	morphology
0.5053456543	predisposing
0.5053456543	constant
0.5053456543	serve
0.5053456543	extreme
0.5053456543	classified
0.5053456543	elucidate
0.5053456543	weak
0.5052111773	95 ci
0.5051401824	target
0.5049998474	periods
0.5048690595	treating
0.5047355404	converting
0.5046822621	remaining
0.5045179866	administered
0.5044135457	showing
0.5044135457	contributing
0.5044135457	partially
0.5044135457	prognosis
0.5041442136	prophylaxis
0.5041442136	alter
0.5041442136	capacity
0.5040479432	outpatient
0.5040479432	strongly
0.5040479432	recordings
0.5037599332	derived
0.5037599332	applied
0.5037023036	estimated
0.5035986680	approach
0.5035986680	electrocardiogram
0.5035343597	completed
0.5035343597	derivative
0.5035153347	benefit
0.5030605334	compared
0.5030188871	marked
0.5028757514	cell carcinoma
0.5028057346	collected
0.5027409082	changed
0.5026296626	provided
0.5022278374	assigned
0.5019592459	enrolled
0.5019592459	successfully
0.5019592459	primarily
0.5019592459	involving
0.5010188871	improved
0.5007158057	improves
0.5007158057	requiring
0.5007158057	asymptomatic
0.5004224013	recognized
0.5004224013	plays
0.4999973673	evident
0.4999277742	attempt
0.4999277742	understood
0.4999277742	solid
0.4999277742	prevents
0.4999277742	parallel
0.4999277742	supports
0.4994967223	experimental model
0.4994252378	acting
0.4994252378	initiated
0.4993653998	treatments
0.4993436941	carried
0.4993436941	directly
0.4993064430	distinct
0.4993064430	produces
0.4993064430	successful
0.4993064430	suffered
0.4993064430	require
0.4990141108	play
0.4985081378	generalized
0.4983910329	studied
0.4981863959	reached
0.4981863959	represent
0.4981863959	prospectively
0.4981863959	problem
0.4979137732	closely
0.4978617307	slightly
0.4978617307	demonstrates
0.4978617307	remain
0.4978617307	persisted
0.4978617307	presenting
0.4975311972	susceptible
0.4975311972	gradually
0.4975311972	uncommon
0.4975311972	withdrawn
0.4971192263	disappeared
0.4971192263	finding
0.4969781422	twice daily
0.4968739666	significantly increased
0.4966419097	ratios
0.4966419097	inhibit
0.4966419097	inducing
0.4957358929	causing
0.4956469864	administration
0.4954269259	renal disease
0.4950252302	significantly decreased
0.4949907019	versus
0.4944544648	stopped
0.4944252737	possibility
0.4942591922	conditions
0.4938700634	warranted
0.4938700634	retrospectively
0.4938700634	shows
0.4935885018	abolished
0.4935885018	substantial
0.4934092682	intravenously
0.4933046377	occurring
0.4932190113	reduces
0.4928438652	ergotamine
0.4924893433	absence
0.4923836420	recovered
0.4923836420	unknown
0.4922496972	comparable
0.4916498127	score
0.4905995872	unclear
0.4905995872	knowledge
0.4900322208	seizure activity
0.4900184108	selected
0.4900091377	levels
0.4899580409	patients receiving
0.4894807272	follow up
0.4890455124	induced
0.4884818094	showed
0.4878763012	longer
0.4876346413	normal
0.4874216335	24 hour
0.4868801257	induced myocardial ischemia
0.4851192508	suspected
0.4850094493	received
0.4845698375	scores
0.4843696467	year old boy
0.4839216013	mg ml
0.4838508724	therapy
0.4835987714	include
0.4835987714	started
0.4828114395	800 mg
0.4824852810	n methyl d
0.4820661789	markedly
0.4818849457	term
0.4818506218	maintained
0.4810981833	overall response rate
0.4808705012	valvular heart
0.4805175144	process
0.4804778319	samples
0.4801505253	recorded
0.4791444986	rapidly
0.4785172884	provide
0.4782465261	matched
0.4778719053	developed
0.4776980449	presence
0.4749578975	chemotherapy
0.4747604754	remains
0.4740375912	k
0.4738280362	response rate
0.4736679440	recommended
0.4733239915	greater than or equal to
0.4717055006	safe
0.4716918308	concluded
0.4705992995	potentially
0.4705675239	achieved
0.4697029133	responses
0.4690706127	medication
0.4686960959	mean + sd
0.4680503179	continued
0.4680503179	occurs
0.4667297663	isoproterenol induced myocardial
0.4663906719	v
0.4662530809	died
0.4649806339	95 confidence
0.4641203313	suggesting
0.4640211756	induces
0.4639212315	once daily
0.4638061592	re
0.4636104415	behavioral effects
0.4633144037	values
0.4632905974	exhibited
0.4630852238	indicating
0.4624670659	monitored
0.4611745095	analyzed
0.4610941688	underwent
0.4610628079	resolved
0.4608891160	occur
0.4608693941	discussed
0.4607351655	findings suggest
0.4606956267	duration of action
0.4605713894	discontinued
0.4604380560	conclude
0.4603669321	demonstrate
0.4603566492	possibly
0.4602919469	pre treatment
0.4599982914	year old girl
0.4592986273	part
0.4589043446	u
0.4588845961	kidney injury
0.4586280067	suggests
0.4581798831	completely
0.4574203099	24 hours
0.4558905875	anti inflammatory drugs
0.4554197088	protection against
0.4553601571	co
0.4544751133	together
0.4533870233	r
0.4520587264	demonstrated
0.4519134813	e
0.4516036514	u ml
0.4500269279	mean arterial pressure
0.4495305230	adenosine receptor
0.4494332513	area under
0.4488128074	120 min
0.4470603838	apomorphine induced
0.4453636224	eight
0.4452970922	no synthase
0.4436203958	seven
0.4434967658	isoproterenol induced
0.4427269333	including
0.4424582226	total dose
0.4423633972	nine
0.4415644057	m
0.4415427796	induced nephropathy
0.4404823989	revealed
0.4400986480	rather
0.4386843524	weeks of treatment
0.4382345617	ranging from
0.4378610463	10 micrograms kg
0.4372739934	neuroleptic induced
0.4363658148	x
0.4362297145	third
0.4350737141	replacement therapy
0.4347353426	t
0.4334573900	last
0.4323413736	induced seizures
0.4321249746	kg ip
0.4319323094	grade 3
0.4317867542	c
0.4298767739	if
0.4291282093	new
0.4290659703	48 h
0.4283176934	sub
0.4280551024	patients undergoing
0.4267068521	overall
0.4257128385	significant differences between
0.4242981695	under
0.4239849352	some
0.4235123526	rat model
0.4225811837	on pod
0.4221151280	b
0.4216375736	n
0.4210827820	compared to controls
0.4200111892	does
0.4190518914	each
0.4173307276	i
0.4168639348	induced encephalopathy
0.4158396500	g
0.4153405890	results suggest
0.4152369533	drug induced
0.4137827836	f
0.4127485314	treated mice
0.4123701051	serious
0.4119475682	lithium induced
0.4119133401	control rats
0.4115651783	o
0.4112828799	s
0.4112343188	h
0.4102486247	l
0.4101342561	no significant differences
0.4099290241	suffering from
0.4093174132	well tolerated
0.4092032800	mg m
0.4091149921	while
0.4088098333	such
0.4086066625	second
0.4064799585	right
0.4060173406	further
0.4054404775	whether
0.4048152102	six
0.4046938382	four
0.4042120638	among
0.4029499555	investigate whether
0.4028347272	adrenaline induced
0.4021895631	dipyridamole induced
0.4017856761	et
0.4013005750	seemed
0.4005963582	p
0.4003737386	p 0.0001
0.3987008986	this article
0.3985374602	five
0.3972637032	ill
0.3963349164	t cell
0.3961925135	few
0.3960604760	allocated to
0.3956554690	most
0.3947797722	name
0.3935705734	three
0.3929332468	mean
0.3925021820	d
0.3924571126	both
0.3919333032	latter
0.3917255866	600
0.3917239646	given
0.3905097290	common side
0.3901462321	widely used
0.3901172068	next
0.3895379018	liver function
0.3890776215	0.0001
0.3881019775	back
0.3879199715	infected patients
0.3878067346	0.7
0.3876866090	fifteen
0.3871984676	no significant difference
0.3870357557	+ 0.7
0.3866112854	systolic blood
0.3860525901	w
0.3849151099	once
0.3848301598	no
0.3845645136	except
0.3842088946	one
0.3841881129	a
0.3837817301	greater than
0.3830704512	patient receiving
0.3829604546	two
0.3828174624	hundred
0.3825142603	800
0.3823480968	thereafter
0.3821932826	+ 0.2
0.3820128193	the present study
0.3818437040	250
0.3817501478	commonly used
0.3816820094	seem
0.3812632369	the
0.3811898876	1.0
0.3810830374	2.0
0.3807523612	these
0.3807045707	37
0.3806108871	after
0.3795798247	along
0.3795531918	400
0.3794553061	y
0.3784668360	75
0.3783013464	all
0.3782136886	control group
0.3781771485	in
0.3780974848	us
0.3776737669	corresponding
0.3773285327	herein
0.3770992129	interaction between
0.3769829185	do
0.3769476576	300
0.3764286439	very
0.3760728049	diastolic pressure
0.3756324517	twelve
0.3744692317	at
0.3741203752	this
0.3736357417	first
0.3733135804	furthermore
0.3727146367	across
0.3722330694	course
0.3719318159	patient developed
0.3717175348	lithium therapy
0.3716771910	150
0.3713641130	ten
0.3712875093	only
0.3711703825	moreover
0.3709509100	the current study
0.3706960352	every
0.3704243006	little
0.3702235292	correlation between
0.3698663220	95
0.3696590324	her
0.3695449390	0.2
0.3689007198	creatinine levels
0.3685535606	before
0.3679399199	often
0.3672098884	an
0.3667431438	people
0.3663212263	forty
0.3662369435	his
0.3661392715	off
0.3660801331	novel
0.3660461192	during
0.3656681919	0.01
0.3654840998	seems
0.3651760503	taken
0.3646237160	as
0.3637625048	value
0.3637210802	twice
0.3636107404	none
0.3634115279	she
0.3628388764	0.1
0.3627709161	throughout
0.3626702300	necessary
0.3626135540	likely
0.3618227347	dose response
0.3612472530	less
0.3609897383	sixty
0.3608421966	0.001
0.3606684559	they
0.3603233848	useful
0.3601451435	nearly
0.3598893021	many
0.3598438967	13
0.3598312594	21
0.3595636901	amount
0.3592184883	120
0.3591780504	since
0.3583399057	neither
0.3576752942	twenty
0.3575545756	80
0.3566568276	here
0.3558957580	plus
0.3558226506	he
0.3556089352	like
0.3551619426	several
0.3551212298	appear
0.3549650178	despite
0.3548357628	upon
0.3546618898	r =
0.3538523118	48
0.3538224524	year old man
0.3530547338	immediate
0.3522367068	need
0.3520461436	other
0.3519386261	until
0.3516987457	these findings suggest
0.3514838617	day
0.3511316844	therefore
0.3502824674	0.05
0.3502202155	1.5
0.3501110674	non
0.3497713316	describe
0.3497033090	almost
0.3497033090	another
0.3486915317	2.5
0.3486699864	500
0.3486362762	selective serotonin
0.3480768131	p 0.001
0.3478425001	later
0.3478000439	especially
0.3475761827	associated
0.3473213098	clinical studies
0.3461336951	0.5
0.3460301604	per
0.3456533212	described
0.3456532282	least
0.3452053367	micrograms kg 1
0.3448601335	year old woman
0.3446350376	up
0.3445675419	known
0.3436916019	mg daily
0.3434843338	year
0.3424636568	system
0.3423767712	following
0.3421601955	also
0.3416668442	more
0.3416582678	100
0.3416384198	old
0.3414730035	against
0.3414577017	currently
0.3414577017	though
0.3412464775	=
0.3412340868	15
0.3412312963	thus
0.3403345233	causes
0.3402947068	p 0.01
0.3401205414	because
0.3401126900	show
0.3400166665	on
0.3396456288	11
0.3395903658	use
0.3394299980	side
0.3392814593	time
0.3390817189	320
0.3388517767	de
0.3387618818	2.0 mg
0.3386155976	24
0.3381549500	end stage
0.3380807908	different
0.3372983025	well
0.3372704766	40
0.3361367482	9
0.3359800385	treated group
0.3357811930	it
0.3356254004	to
0.3355808741	induced cardiomyopathy
0.3352903075	levodopa therapy
0.3352020754	much
0.3352020754	full
0.3350188796	our
0.3349127759	indicate
0.3347031273	regarding
0.3344459731	did
0.3341056805	50
0.3338359244	co administration
0.3333218779	60
0.3332226078	usually
0.3327181430	200
0.3325589864	from
0.3325228558	100 micrograms
0.3324488164	5
0.3315584735	non selective
0.3313902669	then
0.3313049426	cocaine induced
0.3309282296	25
0.3302310008	although
0.3301938575	7
0.3299177594	followed
0.3291341053	within
0.3290864118	drug related
0.3285667345	used
0.3285049686	8
0.3283206675	into
0.3282431507	when
0.3281860910	14
0.3275206382	by
0.3275193124	x 10
0.3274410020	30
0.3274309570	pilocarpine induced
0.3272250069	same
0.3272154770	cause
0.3269513757	catalepsy induced by
0.3266245181	without
0.3260265455	there
0.3237229463	however
0.3236669482	seen
0.3233204815	for
0.3232202293	due
0.3230568383	20
0.3229789747	10
0.3229142219	17
0.3225327768	brief
0.3223888666	whole
0.3223765005	with
0.3219194042	possible
0.3213315687	ranged from
0.3212451376	old girl
0.3212344267	changes
0.3212177379	we
0.3209077369	of
0.3207543865	side effects
0.3205098137	or
0.3204758474	particular
0.3202870726	various
0.3194968043	levodopa induced
0.3190398668	found
0.3189711991	not
0.3189557613	than
0.3186046938	4
0.3186036141	3
0.3185017716	6
0.3182792892	in 3 patients
0.3178827864	300 mg kg
0.3177081570	1
0.3176989039	2
0.3174008629	down
0.3167697520	94
0.3153467824	cocaine use
0.3150405182	using
0.3149167800	induced alf
0.3148397099	induced by scopolamine
0.3147410740	12
0.3144443035	relationship between
0.3141049070	1 or 2
0.3140958763	p 0.05
0.3138988363	between
0.3131966010	shortly after
0.3130830531	days of treatment
0.3127637772	most common
0.3127081138	preceded by
0.3123775571	mg day
0.3108753783	7.5
0.3102033762	+
0.3099450896	0.005
0.3085329142	0.75
0.3078406391	96
0.3077926339	0.002
0.3067142573	66
0.3063993269	6.1
0.3063993269	92
0.3062926339	86
0.3056472454	but
0.3055912586	even
0.3052506032	methamphetamine induced
0.3050434238	001
0.3050288478	disappearance of
0.3046599460	significant reduction in
0.3045039692	a 10
0.3044083863	intravenous infusion
0.3043169302	64
0.3040835875	inner
0.3039028887	58
0.3038172829	appropriate
0.3036124995	0.25
0.3035454540	completion of
0.3034825291	induced catalepsy
0.3030541451	these results suggest
0.3027502933	3.0
0.3022896555	400 mg kg
0.3021655228	1997
0.3021655228	2005
0.3021655228	5.0
0.3021655228	05
0.3016673103	78
0.3010356966	63
0.3007574673	induced cardiotoxicity
0.3004694878	5.4
0.3002831525	grade 3 4
0.3000990450	1.8
0.3000671834	01
0.3000671834	160
0.2997210596	2.3
0.2994134071	induced hypertension
0.2989931713	3.4
0.2988591932	4.1
0.2988591932	79
0.2982422123	2.7
0.2965061809	1.7
0.2965061809	82
0.2964973595	0.5 microl
0.2962487144	33
0.2961512189	most commonly
0.2957588331	0.02
0.2956673866	a dose dependent manner
0.2955847712	less than or equal to
0.2955433419	probably
0.2950999796	whereas
0.2943581067	the dentate gyrus
0.2940862896	determine whether
0.2940341237	51
0.2939866506	135
0.2939866506	77
0.2933901753	125
0.2933660947	400 mg
0.2933466427	1.1
0.2932293280	above
0.2931039587	2002
0.2930820381	so
0.2930635555	otherwise
0.2927988085	certain
0.2927321553	subjected to
0.2924788597	n methyl
0.2922217696	5.6
0.2922217696	3.5
0.2921486915	over
0.2919488656	12.5
0.2919015146	complained of
0.2913877262	3.6
0.2912352458	will
0.2903904454	81
0.2903904454	0.15
0.2899887890	53
0.2899887890	69
0.2899808060	68
0.2897463984	200 mg
0.2893561172	how
0.2893561172	find
0.2891757162	84
0.2891757162	3.2
0.2887239081	near
0.2886051305	and
0.2885576553	rather than
0.2883315643	29
0.2878707960	0.03
0.2876246710	induced hyperprolactinemia
0.2875725306	2004
0.2875522676	lithium treatment
0.2872920821	1.4
0.2866140183	65
0.2865218094	out
0.2864075833	59
0.2861358968	4.5
0.2861216762	76
0.2860043361	46
0.2855675180	available
0.2850563119	67
0.2850446001	induced dyskinesias
0.2849699462	90
0.2847584979	61
0.2846807988	about
0.2845721772	far
0.2845721772	2.8
0.2845721772	74
0.2845721772	1993
0.2845721772	130
0.2843352664	43
0.2842733449	52
0.2828680609	23
0.2827247098	treatment groups
0.2825236661	their
0.2824489831	57
0.2823599635	p less than 0.01
0.2823583559	95 ci =
0.2823427554	2.6
0.2823427554	concerning
0.2823427554	2.1
0.2823427554	consider
0.2823427554	presumably
0.2823427554	below
0.2821103752	via
0.2816865701	took
0.2816865701	344
0.2813003773	41
0.2811018387	itself
0.2810326071	induced nephrotoxicity
0.2807066616	44
0.2806480398	42
0.2804489831	55
0.2803380331	relatively
0.2803117827	1.2
0.2801874169	38
0.2799378604	0.9
0.2798486334	16
0.2794230775	became
0.2793656497	49
0.2793447296	sometimes
0.2793060108	0.3
0.2792909719	22
0.2791798311	45
0.2791425074	help
0.2786168734	54
0.2784994946	older patients
0.2782463029	28
0.2780873632	1.3
0.2779701745	findings indicate
0.2779397647	them
0.2777549176	through
0.2777041811	mg kg body
0.2776863539	36
0.2775902256	70
0.2767463029	32
0.2766403677	can
0.2764425785	mainly
0.2763596146	18
0.2761978478	p less than 0.001
0.2761919623	31
0.2758425785	good
0.2754483205	increased risk
0.2752513178	data indicate
0.2750762029	group b
0.2744806793	0.8
0.2743798786	27
0.2740773521	0
0.2739963533	must
0.2739767818	19
0.2738316869	way
0.2738316869	1.6
0.2738105563	better
0.2736973211	62
0.2736306793	0.6
0.2734128833	1.9
0.2734128833	1000
0.2733464064	39
0.2733464064	34
0.2733259004	tended to
0.2731557518	work
0.2723006917	done
0.2719856123	indicates
0.2718551736	35
0.2717250550	its
0.2716457682	animal models of
0.2715743146	dose related
0.2715269997	still
0.2713682911	fluoxetine induced
0.2713655020	evaluable patients
0.2710651271	60 min
0.2709781887	induced anemia
0.2709724185	best
0.2708692283	those
0.2708085886	26
0.2707787137	any
0.2707473957	now
0.2707473957	again
0.2707473957	cannot
0.2706058816	always
0.2706058816	become
0.2706058816	2.4
0.2704679506	73
0.2702357566	made
0.2690664562	where
0.2688932089	self
0.2688182089	having
0.2682881196	100 mg
0.2681906611	3.8
0.2679015026	alone
0.2677523140	the entire
0.2674682970	the objective of
0.2673824483	containing
0.2672433833	association between
0.2671326931	cardiovascular effects
0.2671224185	72
0.2668983261	one hundred
0.2667535205	warfarin induced
0.2663429518	kg s.c
0.2663335480	side effect
0.2660026651	year old male
0.2657754283	would
0.2653039232	provides
0.2653039232	85
0.2652451321	amphetamine induced
0.2649895606	morphine induced
0.2649868052	whom
0.2643690803	yet
0.2643303326	clearly
0.2643303326	whose
0.2643303326	0.4
0.2643303326	47
0.2641084719	nor
0.2637808125	among women
0.2635915500	indicated
0.2629717097	patients with advanced
0.2628484549	4 neutropenia
0.2626893110	the emergency department
0.2616199825	induced tachycardia
0.2615406455	p less than 0.05
0.2614602660	particularly
0.2606783240	might
0.2604929370	the other hand
0.2598048548	risk factor for
0.2596985477	majority of
0.2595449907	being
0.2590182681	who
0.2576716343	hypertensive rats
0.2564203933	elderly patients
0.2562675009	vs
0.2536749661	patients taking
0.2519814185	induced amnesia
0.2514013074	treated patients
0.2510305282	1.5 mg kg
0.2505529139	should
0.2500114188	could
0.2495529139	respectively
0.2488315450	more frequent
0.2487508465	either
0.2480085046	p or = 0.001
0.2474835683	scopolamine induced
0.2472687192	has
0.2472687192	which
0.2466782430	may
0.2466782430	been
0.2466782430	have
0.2463032430	that
0.2463032430	are
0.2463032430	had
0.2463032430	were
0.2463032430	was
0.2454801796	be
0.2454801796	is
0.2444324219	24 h
0.2443950068	200 mg kg
0.2429411232	+ 0.1
0.2426745668	150 mg
0.2426264027	every 3 weeks
0.2420473756	significant differences
0.2419284122	responsible for
0.2417209514	these data suggest
0.2415577704	most likely
0.2414874463	consecutive patients
0.2405741718	reported cases
0.2405674669	did not differ
0.2399818317	days later
0.2398676879	compared with controls
0.2394791617	difference between
0.2384958044	the majority
0.2382173437	induced dyskinesia
0.2379131761	the blood brain barrier
0.2364144094	accompanied by
0.2354212567	6 months
0.2348653480	drug administration
0.2345999957	year old female
0.2340775878	30 min
0.2328075310	year old
0.2325391961	pd patients
0.2313294584	amiodarone induced
0.2292287549	0.5 mg
0.2291480868	case control
0.2278234080	na +
0.2267892602	patients with cocaine associated
0.2236434627	or in combination
0.2232018976	1 and 2
0.2229751363	like syndrome
0.2228968684	the purpose of
0.2227686338	12 weeks
0.2226733397	treated with
0.2213520539	intravenous administration of
0.2213046154	n =
0.2203146767	100 g
0.2200687551	nicotine induced
0.2197738474	function tests
0.2188752666	500 mg
0.2174191766	kg i.v
0.2168415171	adriamycin induced
0.2166757923	the placebo group
0.2166118916	more frequently
0.2160922231	at least
0.2159458317	upregulation of
0.2155123313	very low
0.2149957334	analysis showed
0.2146569706	300 mg
0.2138191857	induced neurotoxicity
0.2137588978	this paper
0.2136570007	high incidence of
0.2124853997	30 minutes
0.2114880636	able to
0.2108352487	compared with
0.2101674121	does not
0.2100278087	seemed to
0.2097183760	before surgery
0.2093712348	per day
0.2076079448	80 mg
0.2067591867	compared with control
0.2063716381	mg kg day
0.2051295636	assigned to
0.2040461566	contribute to
0.2034244969	bupivacaine induced
0.2024285622	single dose
0.2011346350	p =
0.2011275312	three times
0.2005545714	due to
0.2002834447	old man
0.2001816464	group of patients
0.1988948836	heparin induced
0.1976419144	arterial blood
0.1963234031	determine if
0.1961314323	1.0 mg
0.1960892794	after liver transplantation
0.1956990676	100 mg kg
0.1956829453	while taking
0.1955948957	a group of
0.1949632788	adverse drug
0.1949604740	did not change
0.1948289755	results showed
0.1946113158	contributes to
0.1940482216	more potent
0.1924952575	plus maze
0.1923116734	min before
0.1921919051	did not
0.1921228708	characterized by
0.1905948957	the addition of
0.1900998321	oral administration of
0.1893952865	during pregnancy
0.1884557122	patients experienced
0.1878798078	defined as
0.1876464991	2.5 mg
0.1871993372	600 mg
0.1868144113	used to treat
0.1846185104	increase in heart
0.1836720535	differences between
0.1831741035	one month
0.1826721447	high doses of
0.1817983438	regardless of
0.1813449752	do not
0.1804096898	well known
0.1798365347	blocked by
0.1786427396	an important role
0.1777067387	120 mg
0.1776338580	meth induced
0.1773421593	kg i.p
0.1766263788	an increase of
0.1764942049	long term use
0.1748838878	haloperidol induced
0.1742943308	activity against
0.1741524434	year period
0.1739071530	an increased risk
0.1737761600	induced by
0.1734854297	caused by
0.1721602623	dox induced
0.1714380443	4 weeks
0.1712025955	five cases
0.1707958743	increased significantly
0.1704972711	with or without
0.1704835479	15 min
0.1699479329	10 mg kg
0.1699452579	mg kg per day
0.1698479611	0.5 mg kg
0.1696023419	40 mg kg
0.1689819938	to assess
0.1688425026	thought to
0.1678149330	+ sd
0.1677889281	did not affect
0.1669605854	according to
0.1658320925	more common
0.1656792508	the safety and
0.1654895301	plasma levels of
0.1654308792	intravenous infusion of
0.1652747198	this study
0.1650072692	8 weeks
0.1646890173	patients received
0.1635990060	as well as
0.1613482802	resulting from
0.1608411556	in conjunction with
0.1605213382	an unusual
0.1603756686	beta 2
0.1600200763	6 weeks
0.1593948809	with and without
0.1589196571	acetaminophen induced
0.1583128825	intravenous administration
0.1575725347	25 mg
0.1575667883	risk factors for
0.1571229510	a variety of
0.1569320536	leading to
0.1568742963	patients with
0.1567057927	min 1
0.1565801599	50 mg kg
0.1554904265	blind study
0.1551229510	in contrast to
0.1541645025	by means of
0.1538797078	with respect to
0.1530577698	cyclophosphamide induced
0.1528797078	in terms of
0.1520838796	20 mg kg
0.1509807145	group c
0.1508968212	aminonucleoside induced
0.1502887072	the passive avoidance
0.1502487000	dexamethasone induced
0.1488116632	a significant reduction
0.1487857697	a case report
0.1487240741	30 min before
0.1486586584	associated with
0.1485796762	doxorubicin induced
0.1484985354	a double blind
0.1483491856	six cases
0.1473717532	kg per day
0.1465644386	a dose
0.1462545430	patients developed
0.1460572507	protective effect of
0.1455341028	30 mg kg
0.1447002444	behavioral effects of
0.1445392395	ci =
0.1441850855	risk patients
0.1437816064	six months
0.1436638590	induced muscle
0.1435621609	acute myocardial
0.1434873266	acid induced
0.1433600402	the same
0.1421450039	= 0.01
0.1420705092	5 mg kg
0.1416897080	experimental model of
0.1416096038	a significant decrease
0.1414169078	continuous infusion of
0.1413576104	safety and efficacy of
0.1408888210	failed to
0.1408668367	induced acute
0.1399899662	the treatment
0.1395942687	in order to
0.1394909023	did not produce
0.1394533548	oral administration
0.1394330282	attributable to
0.1393690510	group received
0.1390435388	mean age
0.1388447524	7 days
0.1383015047	both groups
0.1374841534	attributed to
0.1374508671	microinjection of
0.1374137954	old woman
0.1371473478	observed in patients
0.1370896357	consistent with
0.1368412520	animals treated with
0.1368254294	effects of
0.1361773853	related to
0.1361172183	the aim of
0.1360200794	increased risk of
0.1345797971	year old patient
0.1344148654	a phase ii
0.1342393367	patients with severe
0.1341451171	lack of
0.1337369818	led to
0.1333920122	20 mg
0.1325793933	10 mg
0.1321889396	myocardial infarction in
0.1313748989	patients with parkinson's disease
0.1305167837	lower than
0.1291059032	seizures induced by
0.1286841194	showed significant
0.1283455438	numbers of
0.1277986251	40 mg
0.1270848801	50 mg
0.1268620878	based on
0.1268359256	this case
0.1266528123	cessation of
0.1265160251	the control group
0.1263944905	patients treated with
0.1261015158	adult patients
0.1259526774	serum levels
0.1253208136	animals treated
0.1253032031	serum levels of
0.1251384315	rats received
0.1249409377	hypotension induced by
0.1247063496	such as
0.1236258379	higher than
0.1235611039	resulted in
0.1235391300	more often
0.1234875545	disruption of
0.1229970299	to achieve
0.1229234130	the effect
0.1227210797	to determine
0.1221193154	a dose dependent
0.1217184749	ventricular function
0.1213363053	in combination with
0.1209099662	of rats
0.1205436544	significantly less
0.1201920997	these data indicate
0.1198773449	appear to
0.1193751813	not to
0.1190525271	on days 1
0.1185328311	appears to
0.1179847661	6 hours
0.1179052344	cancer patients
0.1174696571	a case of
0.1172676392	20 min
0.1166950072	more likely to
0.1164474380	predictors of
0.1164064163	time course
0.1153444030	p p
0.1152435305	the changes in
0.1150329681	fall in
0.1148817565	plasma concentrations of
0.1147602233	mg kg per
0.1146202177	in addition
0.1145158692	an increase in
0.1136480095	transplant patients
0.1136277000	consequence of
0.1134995868	these observations
0.1132373967	these results indicate
0.1131691582	four weeks
0.1131356843	while receiving
0.1131067796	the heart rate
0.1121915732	used to evaluate
0.1119926824	a prospective study
0.1115892537	of levodopa therapy
0.1105691481	suggestive of
0.1103094647	one week
0.1103007085	of cocaine induced
0.1101112453	p less than
0.1097234686	significantly more
0.1096701347	leads to
0.1093567156	the striatum
0.1091415692	correlated with
0.1090278323	less than
0.1089192743	produced by
0.1089025477	a single dose
0.1084780197	developed acute
0.1084763120	aimed to
0.1084389574	effect of
0.1083084245	patients treated
0.1080373167	to determine if
0.1069189863	in patients receiving
0.1066616969	induced increase in
0.1060562204	1 month
0.1057183277	a rat model
0.1052439923	plasma levels
0.1052436028	mg kg 1
0.1052143218	5 mg
0.1051420665	4 days
0.1047529529	30 micrograms
0.1035620888	the control
0.1028423822	these findings
0.1027537544	renal function in
0.1025899167	placebo group
0.1023519737	in cancer patients
0.1018815763	old male
0.1014866861	1.5 mg
0.1011810531	seem to
0.1011480853	significantly lower in
0.1011162872	+ 7
0.1008376924	no difference
0.1006602584	8 days
0.1005021944	immediately after
0.1003410160	the results
0.1000683411	a significant increase
0.1000609663	observed between
0.0999121992	with regard to
0.0997799733	ii study
0.0996877602	further studies
0.0996420154	amounts of
0.0993705717	drug therapy
0.0986495055	in elderly patients
0.0984929057	hours after
0.0979947273	pretreated with
0.0976701347	referred to
0.0974689578	to evaluate
0.0973421362	significantly different
0.0972943465	1 mg kg
0.0970828295	to estimate
0.0968128864	effective treatment
0.0968044380	12 months
0.0967721230	a total of
0.0967403262	followed by
0.0964827361	case of acute
0.0958155889	susceptibility to
0.0957773686	less than 0.05
0.0957747846	adverse effect of
0.0955742607	1 hour
0.0955430205	in patients with acute
0.0952451197	treatment with
0.0951075282	an important role in
0.0932580738	75 mg
0.0926358499	rats treated
0.0925089608	than 50
0.0921742927	administration of
0.0918930930	3 weeks
0.0918756383	designed to
0.0917563439	the risk
0.0911956315	long term use of
0.0909069767	the first case
0.0908744452	rats treated with
0.0907502235	no significant
0.0907420207	the effects
0.0907217866	this patient
0.0900580789	no differences
0.0900259806	returned to
0.0890865175	in rats
0.0889182280	14 days
0.0888930160	the possibility
0.0888810001	significant increase
0.0888192946	mg kg for
0.0886971299	measurement of
0.0881630005	3 mg kg
0.0876247348	5 min
0.0874481792	at baseline
0.0871948437	seems to
0.0871721627	induced increase
0.0870063286	+ 8
0.0867932344	the long term
0.0867355566	induced by haloperidol
0.0864854975	to examine
0.0862083705	adverse effects of
0.0860967925	to avoid
0.0859521685	one patient
0.0858955828	each patient
0.0857508220	one year
0.0855589937	acute renal
0.0852555632	resulting in
0.0852258523	to determine whether
0.0851903329	consisted of
0.0851022029	= 2
0.0849857926	these data
0.0848010266	day of
0.0847399062	patients with cocaine
0.0837190145	4 mg kg
0.0835759045	acute liver
0.0831643608	10 micrograms
0.0830296981	kg 1
0.0829612925	affected by
0.0829577755	significant difference in
0.0828030818	+ 6
0.0827954176	+ 1
0.0824076315	induced hypertension in
0.0819234873	+ 3
0.0818761199	this complication
0.0815060561	mg day for
0.0813775688	the patient
0.0813768007	significantly higher in
0.0809826184	sufficient to
0.0806963545	3 months
0.0805967925	to detect
0.0804256980	the patient developed
0.0803848653	the authors
0.0802891090	an alternative
0.0801115169	compared to
0.0799332726	n = 6
0.0798405433	lead to
0.0797778387	4 mg
0.0796242296	n = 7
0.0795642884	for 3 days
0.0788831200	decline in
0.0788533707	and also
0.0787893408	rat model of
0.0785571672	a case of acute
0.0783232417	present study
0.0782996248	after conversion
0.0781933400	all patients
0.0779563455	a patient with
0.0776242435	as part of
0.0775824661	modulation of
0.0773309443	among patients
0.0772680411	n = 8
0.0771575964	in patients undergoing
0.0771542030	10 days
0.0771058183	studies in
0.0769711618	aware of
0.0769599105	the injection of
0.0768781048	in patients with
0.0765697105	three groups
0.0760825698	250 mg
0.0760337222	an average
0.0760032726	presence of
0.0759880795	the inhibition of
0.0756952571	to investigate
0.0756222503	the basis of
0.0755961463	in vitro
0.0755314983	or =
0.0752748818	4 months
0.0751457591	in two patients
0.0749794300	and only
0.0747089534	one or more
0.0746188455	the development of
0.0744908470	+ 2
0.0743460770	0.1 mg
0.0740731036	of patients
0.0740501539	+ 10
0.0739915414	to treat
0.0738918367	1 year
0.0738353659	n = 10
0.0735731036	in patients
0.0734781971	cocaine associated
0.0734087118	+ 4
0.0733228847	5 days
0.0731196746	these results
0.0729351279	absence of
0.0727633782	to explore
0.0720912602	results show
0.0718922122	the time
0.0714542076	days after
0.0713834861	doses of
0.0712984348	equal to
0.0707576638	proportion of
0.0706364167	2 mg kg
0.0703403563	induced myocardial
0.0698709000	the treatment of
0.0698009123	these patients
0.0696997903	alpha 2
0.0696230995	two groups
0.0692617185	or not
0.0689455944	an important
0.0686770534	+ 5
0.0686768265	before and after
0.0681271879	days 1
0.0680037327	more than
0.0679278381	to identify
0.0676527320	follow up of
0.0674986869	15 mg kg
0.0674260266	changes of
0.0671791468	the development
0.0671628834	and in vivo
0.0666372119	result from
0.0664314021	superior to
0.0660907317	but not
0.0659361477	an effective
0.0656827753	no effect on
0.0655766667	contribution of
0.0653690729	latency to
0.0653277043	a control
0.0651430557	among groups
0.0647264974	effect on
0.0647178701	the cause of
0.0646055968	the risk of
0.0645284145	undertaken to
0.0644259259	these agents
0.0644142857	induced liver
0.0642984724	2 weeks
0.0640890236	a significant increase in
0.0637322302	3 years
0.0630539526	the occurrence of
0.0629184621	the effects of
0.0628657718	incidence and severity of
0.0624457637	n = 12
0.0623950373	before and
0.0621278954	mediated by
0.0620376680	manifestation of
0.0620373723	four groups
0.0619197748	the patient's
0.0619139511	suppression of
0.0616986161	the hippocampus
0.0616624553	assessed by
0.0615409307	year old woman with
0.0614955563	increase in
0.0609262539	the use of
0.0607904778	2 cases
0.0606470169	minutes after
0.0603129208	two cases
0.0602952330	all cases
0.0602160541	t +
0.0601363010	exposed to
0.0600172560	a single
0.0596982836	in 1 patient
0.0595695034	to compare
0.0593612630	the central nervous system
0.0593595185	a complication
0.0592572040	secondary to
0.0591191978	a case
0.0590992211	rare but
0.0590981910	hr after
0.0590175445	single dose of
0.0586897243	disease patients
0.0586113627	the first
0.0584034755	these drugs
0.0583925348	a day
0.0583221344	the presence of
0.0580721554	the changes
0.0579184621	the effect of
0.0575668140	a model
0.0574258770	a reduction
0.0571889869	regulation of
0.0570058296	mean +
0.0567883266	admitted to
0.0565258230	these cases
0.0563406369	isolated from
0.0561784013	15 mg
0.0551966411	the drug
0.0549426749	this effect
0.0546966411	the study
0.0546964452	as measured by
0.0546868330	improvements in
0.0546223186	group 2
0.0544638463	reduction of
0.0544376882	the levels of
0.0540199308	in rodents
0.0533942100	of patients in
0.0532930607	other drugs
0.0531247543	time of
0.0525811712	in rats treated
0.0525658556	mg per
0.0524568305	efficacy and safety of
0.0523697740	implications for
0.0523402505	hypertension in
0.0523024680	system to
0.0522837521	to investigate whether
0.0520987126	p or =
0.0518504578	the literature
0.0518416577	ability to
0.0517332525	effects on
0.0515136446	at week
0.0514223790	the mechanisms of
0.0513177384	a phase
0.0512719600	in vitro and in vivo
0.0512345185	the expression
0.0510897278	each group
0.0510617670	group 1
0.0510615921	between groups
0.0508379760	the procedure
0.0503823790	the risk for
0.0502537394	prior to
0.0502465371	the number
0.0501229315	5 years
0.0500768852	3 times
0.0500376609	more likely
0.0498922894	5 patients
0.0498288799	use in
0.0498226746	both drugs
0.0496849437	in rats treated with
0.0494725042	report on
0.0492951915	determined by
0.0491263061	a significant decrease in
0.0490961604	old female
0.0488816792	the cause
0.0487244610	the present
0.0487041503	the pathophysiology of
0.0485406506	for patients with
0.0485353831	used with
0.0485351374	prevalence of
0.0485326739	comparison with
0.0481778976	but not in
0.0481351770	first time
0.0481083236	a single dose of
0.0478410211	the number of
0.0478007240	the increase in
0.0478007240	of patients with
0.0478007240	the dose of
0.0477589055	dose of
0.0475865546	significant decrease in
0.0475147830	30 mg
0.0474584305	60 mg
0.0473841575	to date
0.0473744606	use of
0.0473653880	confirmed by
0.0473107918	= 5
0.0471675514	in doses of
0.0469823818	the hypothesis
0.0468016406	one case
0.0467007205	kg per
0.0464941226	the ability of
0.0463484884	year old man with
0.0463401697	an increased
0.0463011918	role of
0.0460716422	the liver
0.0460632736	no change
0.0460629857	these studies
0.0458066148	for 14 days
0.0457502371	the magnitude of
0.0456693188	for 2 weeks
0.0454740499	response to
0.0454540476	the need
0.0453804683	an inhibitor of
0.0453360069	24 h after
0.0453078651	a median
0.0452759144	decreases in
0.0451857445	infections in
0.0451604292	this drug
0.0451584872	not associated with
0.0446932785	12 mg
0.0446565017	13 patients
0.0446418490	initiation of
0.0445389956	day 2
0.0442992013	in most
0.0442183836	given to
0.0441489125	seven patients
0.0441403410	except for
0.0441216432	for 7 days
0.0440592149	incidence of
0.0440587713	in adults
0.0439644536	the incidence of
0.0439243580	this syndrome
0.0438691901	two cases of
0.0438484017	depletion of
0.0438458144	enhancement of
0.0437283707	a well
0.0435808642	the right
0.0435144286	reversed by
0.0434982869	the same time
0.0433707577	as to
0.0433678247	with risperidone
0.0433619962	changes in
0.0432299220	in rats with
0.0431739741	conversion to
0.0431616354	the administration of
0.0431208102	the first reported
0.0430025548	involved in
0.0429785662	the role of
0.0429387896	one day
0.0429207678	these effects
0.0428649440	inhibited by
0.0428593756	the end of
0.0426469757	obtained from
0.0423218124	the results of
0.0423188005	women on
0.0422880130	regard to
0.0420771463	evoked by
0.0419741603	in one patient
0.0418609486	a patient
0.0417903828	the two groups
0.0417833469	1 week
0.0415657308	the brain
0.0412772062	lidocaine in
0.0410966647	in users of
0.0410153433	a significant
0.0409983422	a mean
0.0409732029	reversal of
0.0409274442	not previously
0.0408770056	used in
0.0408593756	the pathogenesis of
0.0408305970	mean arterial
0.0407146718	tolerability of
0.0406758381	considered as
0.0406726352	the onset
0.0406365321	amount of
0.0405762865	signs of
0.0405687965	observed in
0.0405442730	impact of
0.0402757037	group than
0.0401091960	the decrease in
0.0401028570	start of
0.0399944678	results indicate
0.0398609031	from baseline
0.0397554522	data from
0.0397071669	the time of
0.0396755281	in mice
0.0396389601	cases of
0.0395612682	pretreatment with
0.0394907460	11 patients
0.0394307890	the prevalence
0.0392051589	increased to
0.0391006177	actions of
0.0390523970	implicated in
0.0388770828	the rat
0.0388482742	an additional
0.0387691723	in humans
0.0384969792	along with
0.0384252303	increased from
0.0383934031	neurons in
0.0383655056	a history of
0.0383034131	2 h
0.0382527180	length of
0.0381898044	the expression of
0.0380352998	after initiation of
0.0379873690	two patients with
0.0379619955	number of
0.0379134244	the efficacy and safety
0.0379126696	application of
0.0379072659	in patients treated with
0.0378685024	the last
0.0378148618	types of
0.0377980960	appearance of
0.0377919592	children with
0.0377464189	a combination of
0.0376500444	five patients
0.0376202315	case of
0.0375150097	the activity of
0.0374799844	cells in
0.0374140431	this model
0.0373655056	a decrease in
0.0372684441	an open
0.0371616354	a dose of
0.0371529664	a result
0.0370659241	also showed
0.0369578284	relation to
0.0369468620	every 3
0.0368764262	2 years
0.0365395078	prevented by
0.0363894577	h after
0.0362805606	a retrospective
0.0361706148	in doses
0.0361036273	the presence
0.0359985178	development of
0.0359203770	the induction of
0.0356845412	the efficacy of
0.0356675514	the incidence and
0.0355923577	1 mg
0.0355357587	four patients
0.0354672607	loss of
0.0354657145	component of
0.0354351843	eight patients
0.0354299916	content of
0.0353472913	the regulation of
0.0352939973	patterns of
0.0352648798	evidence of
0.0352619872	distribution of
0.0352292242	time course of
0.0352275042	presented with
0.0352165549	a novel
0.0352096175	infusions of
0.0352020586	a cause
0.0350812092	comparison of
0.0350731371	14 patients
0.0350218819	activity in
0.0349715896	dyskinesias in
0.0349168091	the severity of
0.0347488494	the course of
0.0347418885	2 mg
0.0347242506	day after
0.0346385150	an increased risk of
0.0344710718	damage to
0.0344473894	the efficacy and
0.0343765120	a reduction in
0.0343454574	in association with
0.0342668985	the case of
0.0342299220	the level of
0.0341516710	history of
0.0341356865	courses of
0.0340534686	these changes
0.0339630617	first case
0.0339205528	role in
0.0337994284	degeneration of
0.0336883479	region of
0.0336346627	in women with
0.0336235014	failure after
0.0336090258	during treatment with
0.0334211527	resolution of
0.0333820934	in children
0.0333655056	the absence of
0.0332409983	or more
0.0330169934	the time course
0.0329885047	by scopolamine
0.0329644211	not affected
0.0329383598	recurrence of
0.0328177762	reduction in
0.0327989847	occurred after
0.0327194717	shown to
0.0326566418	and safety of
0.0325933144	1 h
0.0325600848	detection of
0.0324376332	thrombosis in
0.0324172136	a strong
0.0323655056	the influence of
0.0323542175	a result of
0.0323268025	the first time
0.0322575633	nine patients
0.0321791390	combined with
0.0321045266	days of
0.0320915826	woman with
0.0320271305	a combination
0.0320232374	3 mg
0.0319502944	required for
0.0318411639	means of
0.0316734982	and severity of
0.0315380375	to reverse
0.0314604590	after discontinuation of
0.0312900512	a review of
0.0312696975	after starting
0.0312525244	antagonism of
0.0312410489	a role in
0.0311739707	inhibition of
0.0310731089	a decrease
0.0310677141	none of
0.0309168278	occurred in
0.0309134232	only one
0.0308706400	duration of
0.0308175765	relative to
0.0308170906	injected with
0.0306958574	and efficacy of
0.0306845412	in children with
0.0306328640	the percentage
0.0306224100	a multicenter
0.0306090258	at doses of
0.0305549322	the diagnosis of
0.0304879724	6 h
0.0304848013	increased with
0.0304804577	criteria for
0.0304734312	the effectiveness of
0.0303525022	a rat model of
0.0303252085	the rate of
0.0303035838	determination of
0.0302702717	an association
0.0302629817	injection of
0.0301592289	percentage of
0.0300503734	three patients
0.0300355959	to improve
0.0299327153	no effect
0.0298728276	for treatment of
0.0298728276	a model of
0.0298050497	no evidence
0.0297465534	therapy with
0.0297348978	importance of
0.0296510112	the next
0.0296453451	treatment for
0.0295979428	need for
0.0295757781	the basis
0.0295716812	reductions in
0.0295529614	this report
0.0295172397	after exposure to
0.0294544826	the percentage of
0.0293936650	the magnitude
0.0293371358	day 1
0.0293294208	reported with
0.0292437983	detected in
0.0292290604	need to
0.0291416471	together with
0.0291320242	time to
0.0291305284	resistant to
0.0291067793	the latter
0.0291010628	ingestion of
0.0290906047	the mechanism of
0.0290265512	and tolerability of
0.0289807478	a marker
0.0288621789	the results indicate
0.0288582145	exposure to
0.0287773778	form of
0.0287235866	comparison to
0.0286465099	a period of
0.0285837801	a risk
0.0285661202	the initiation of
0.0285304879	patient with
0.0284505645	needed to
0.0283915225	the extent of
0.0283349453	the duration of
0.0282069252	similar to
0.0281275524	the duration
0.0281173470	rise in
0.0279930999	the efficacy and safety of
0.0279835194	also significantly
0.0279796282	to receive
0.0279682855	six patients
0.0279639759	function in
0.0278921821	as compared with
0.0277930999	the start of
0.0277930999	the importance of
0.0277737611	side effect of
0.0277165494	elevation of
0.0276949944	discontinuation of
0.0276750575	site of
0.0276746789	the combination of
0.0276412218	course of
0.0276226874	drugs in
0.0275995750	the management of
0.0275717603	expression of
0.0275458824	no evidence of
0.0274917914	necessary to
0.0273775524	the end
0.0273560562	accumulation of
0.0273497634	old man with
0.0273229514	excretion of
0.0272844681	role for
0.0272584961	the incidence
0.0272230411	to prevent
0.0272150515	a series of
0.0271865637	higher in
0.0271839776	as compared to
0.0271697044	users of
0.0271550545	area of
0.0271420487	correlation with
0.0271249288	decreased from
0.0271099436	the incidence and severity of
0.0270647125	1 patient
0.0270624357	after treatment with
0.0269632623	rats with
0.0269213672	for more than
0.0267389143	risk of
0.0266746789	no change in
0.0266327281	evidence for
0.0265691046	records of
0.0265595412	the degree of
0.0265532819	this agent
0.0262348093	treated for
0.0262116611	evaluation of
0.0261801366	secretion of
0.0261361178	the pathophysiology
0.0261167072	the mechanism
0.0260083908	sensitive to
0.0259967518	first reported
0.0259691949	3 days
0.0259108296	formation of
0.0259009966	the prevention of
0.0259009966	the involvement of
0.0259005910	to measure
0.0258587251	described in
0.0258448638	at doses
0.0257787926	kg day
0.0257630691	the initiation
0.0256998781	the degree
0.0256666505	no other
0.0255841529	a number of
0.0255384766	appeared to
0.0255338050	other than
0.0254565561	the amount of
0.0254375629	in response to
0.0254202853	as well
0.0253791939	in addition to
0.0253276764	to cause
0.0253098353	differences in
0.0253043056	the progression of
0.0252983631	the possibility of
0.0252090258	the safety of
0.0251183331	the past
0.0250759098	diagnosed with
0.0249145101	the relationship between
0.0248913758	the need for
0.0248744660	the onset of
0.0248448590	the appearance of
0.0248395172	a population
0.0247960890	side effects of
0.0247455921	after administration of
0.0247386422	association with
0.0246442323	two patients
0.0246104713	treatment of
0.0245041182	the frequency of
0.0245016649	used to
0.0244855245	blockade of
0.0244742542	extent of
0.0244724360	for at least
0.0244093126	episodes of
0.0242907940	improvement in
0.0242853173	reduced by
0.0242090258	the prevalence of
0.0241034573	evaluated by
0.0240915212	weeks after
0.0240821017	therapy for
0.0240768358	degree of
0.0240053589	an acute
0.0239189739	used as
0.0238258969	known to
0.0238249471	a rare
0.0237921587	a prospective
0.0237367191	weeks of
0.0237015846	all three
0.0236109864	found to
0.0235698649	pathogenesis of
0.0235176330	not significantly
0.0234533638	to develop
0.0234267812	to induce
0.0234093502	properties of
0.0233547872	carcinoma of
0.0233211778	observed at
0.0232294781	features of
0.0231149770	an experimental
0.0230998801	pattern of
0.0229341947	to produce
0.0229281171	activation of
0.0229105641	activity of
0.0229009966	the association between
0.0227766521	a major
0.0227591060	dogs with
0.0227579354	on days
0.0227416893	reported to
0.0224180151	progression of
0.0223603935	safety of
0.0223425484	frequency of
0.0223305356	the emergency
0.0223059506	on day
0.0223053725	the effectiveness
0.0222296551	action of
0.0222218784	data on
0.0221082034	infusion of
0.0220569075	measured in
0.0220473093	observed with
0.0219818299	2 days
0.0219753576	found in
0.0219648681	change in
0.0219042924	min after
0.0218987031	1 day
0.0218974334	dosage of
0.0217997987	a history
0.0217963359	analysis of
0.0217950790	sensitivity to
0.0217624213	period of
0.0217431686	decrease in
0.0217222091	performed on
0.0216494902	assessment of
0.0215709742	model of
0.0215217464	level of
0.0214599454	tested for
0.0214342036	some patients
0.0214236902	randomized to
0.0213591394	percent of
0.0213103090	prevention of
0.0213072837	models of
0.0212504432	alterations in
0.0212461448	induction of
0.0212313578	complication of
0.0212134531	in vivo
0.0212069452	levels of
0.0210892864	an early
0.0210316106	administered at
0.0209849688	reported in
0.0209255867	the amount
0.0209174075	the absence
0.0209105641	toxicity of
0.0208209742	onset of
0.0207786843	basis of
0.0207748805	production of
0.0207669329	reports of
0.0206935025	markers of
0.0206755866	release of
0.0205364994	injections of
0.0204755703	mechanisms of
0.0204741274	recovery of
0.0204288715	dependent on
0.0204210983	activities of
0.0204156960	cause of
0.0203632378	day for
0.0203603935	months after
0.0203266799	patients without
0.0202781962	performed to
0.0202492135	administered as
0.0201891913	to reduce
0.0201543076	concentration of
0.0201114869	effectiveness of
0.0200938620	women with
0.0199813616	management of
0.0198141001	expression in
0.0197057049	to moderate
0.0196451406	episode of
0.0195938066	intensity of
0.0195082247	greater in
0.0194051351	years after
0.0193715695	symptoms of
0.0193603935	injury in
0.0193089037	noted in
0.0192792875	evaluated in
0.0192446451	factor for
0.0192406171	increases in
0.0191456409	different from
0.0191264602	risk for
0.0191152092	measured by
0.0190741634	21 patients
0.0190642233	likely to
0.0190525769	quality of
0.0190435499	result of
0.0190295317	end of
0.0187551160	value of
0.0187135673	ability of
0.0186364994	diagnosis of
0.0185704991	part of
0.0185595197	introduction of
0.0185309717	withdrawal of
0.0184550458	review of
0.0184492583	assessed in
0.0184223234	used for
0.0184076879	marker of
0.0182554040	rate of
0.0182480511	a few
0.0182377043	a new
0.0182047974	reaction to
0.0182017608	administered to
0.0181114741	moderate to
0.0180777710	manifestations of
0.0179955623	model for
0.0179906171	concentrations of
0.0179517608	rates of
0.0179336214	presented to
0.0178862037	increased by
0.0178537040	examined in
0.0178537040	investigated in
0.0178186163	performed in
0.0177867129	the extent
0.0177232012	combination with
0.0177228371	included in
0.0176466178	elevation in
0.0175938066	areas of
0.0175476384	studied in
0.0174663556	profile of
0.0173919053	but only
0.0173296533	combination of
0.0173086214	considered to
0.0172143051	type of
0.0172071727	effects such as
0.0170796533	obtained in
0.0170564960	and then
0.0169500950	lower in
0.0168118847	a role
0.0167000950	identified in
0.0166597900	impairment of
0.0166247698	considered in
0.0165611399	especially in
0.0165325916	range of
0.0164877855	mechanism of
0.0164752881	examination of
0.0164643051	trial of
0.0164543101	characteristics of
0.0163572054	examined for
0.0163568176	not only
0.0163235871	conducted in
0.0162876434	maintenance of
0.0162432884	half of
0.0162143051	stimulation of
0.0161282740	treated by
0.0160392229	performed with
0.0160045875	seen in
0.0159154703	but also
0.0158841419	difference in
0.0158478371	tested in
0.0158227312	size of
0.0158186163	efficacy of
0.0157094045	man with
0.0155641076	to describe
0.0155290026	deterioration of
0.0155112149	up to
0.0155070235	observed after
0.0154008835	causes of
0.0153972054	daily for
0.0153579897	suggested to
0.0152948068	inhibitor of
0.0150590694	appeared in
0.0150448068	determined in
0.0149902969	deficits in
0.0147555911	involvement of
0.0146906437	a useful
0.0146127339	potential for
0.0145659266	addition to
0.0144803254	series of
0.0144104841	influence of
0.0141466653	occurrence of
0.0140982850	severity of
0.0136600950	ratio of
0.0120426708	aim of
